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ABSTRACT 
Magnetic resonance imaging is a viable medical imaging tool with a very good 
spatial resolution, but with a relatively low sensitivity. By coupling MRI to 
another very sensitive technique such as optical imaging, complementary 
information could be obtained. This manuscript covers the development of 
different multimodal contrast agents for the use in optical and magnetic resonance 
imaging. 
 
In a first approach to develop these bimodal contrast agents, the synthesis and 
characterization of two DTPA based heteropolymetallic lanthanide metallostar 
complexes with the general formula (GdL1)3Ln, (GdL2)3Ln and (GdL3)3Ln are 
described. The synthesis uses a novel synthetic approach, recently developed in 
our group, towards the selective incorporation of gadolinium(III) and a 
luminescent lanthanide ion into a bitopic ligand, resulting into a highly 
paramagnetic and luminescent metallostar complex. Due to the higher excited 
state of L1, a better sensitization was observed in all (GdL1)3Ln complexes as 
compared to (GdL2)3Ln. A large increase of the quantum yield from 1.5% to 9.8% 
was observed for the (GdL1)3Eu complex compared to (GdL2)3Eu, while the 
(GdL1)3Tb complex exhibited a quantum yield of 30.9%, compared to 15.3% 
observed for (GdL2)3Tb. A slight increase of the quantum yield from 0.8% to 
1.2% was observed for the Dy(III) complex when switching from ligand L2 to L1. 
The NMRD measurements of the (GdL2)3Ln complexes (Eu(III), Dy(III), Tb(III)) 
showed longitudinal relaxivity values r1 of 24.27, 22.80 and 21.72 s-1mM-1 
respectively per metallostar complex at 310 K and 20 MHz.  
In a second approach small monodisperse multimodal iron oxide nanoparticles 
were functionalized with three novel boron-dipyrromethene (BODIPY) 
derivatives, which are covalently attached to the nanoparticles surface via thiolene 
 ii 
click chemistry. Luminescent properties and cell viability studies of the 
nanoparticles have been evaluated. Bright fluorescence at 538, 594 and 661 nm is 
observed for nanoparticles with BDP1, BDP2 and BDP3 respectively. Cell 
viability studies on rat tumor (AR42J) and human ovarian cancer (SKOV3) cells 
showed no significant cytotoxicity up to a concentration of 200 µg/ml. Human 
hepatic stellate (GRX) cells were only significantly affected by the NPs at the 
highest concentrations. 
In a third approach a novel gadolinium(III) DOTA complex functionalized with a 
BODIPY dye obtained via copper mediated cycloaddition is reported. The 
assembly of the complex relies on azide diazotransfer chemistry in a copper tube 
flow reactor. The azide thus formed is coupled directly with an alkyne via copper 
mediated cycloaddition, resulting into a paramagnetic and luminescent 
gadolinium(III) complex. The complex displays a bright emission at 523 nm with 
an absorption maximum of 507 nm with a high quantum yield of 83% in water. 
The proton relaxivity of the complex measured at 310 K and at frequencies of 20 
and 60 MHz had the values of 3.9 and 3.6 s-1mM-1, respectively. 
In a last approach peptide chemistry is used to synthesize a novel DOTA-BODIPY 
derivative. Unfortunately, a final complex could not be obtained, as the BODIPY 
core was destroyed during a deprotection step. The synthesis and characterization 
of two La-DOTA chelates with BODIPY derivatives, La-DOTA-BDP4 and La-
DOTA-BDP5, is also highlighted. The azide containing BODIPY derivatives are 
reproduced from literature and coupled to a La-DOTA complex via copper 
mediated cycloaddition. The resulting complexes are water-soluble and exhibit 
good fluorescent properties. Upon ligand excitation a bright emission in water was 
observed at 508 and 510 nm with quantum yields of 39% and 64% for La-DOTA-
BDP4 and La-DOTA-BDP5 respectively. Gadolinium(III) containing derivatives 
should be synthesized to measure the relaxometric properties. Due to the similar 
size, it is expected that the relaxivity of these compounds will be in the range of 
previously reported values for Gd-DOTA complexes.  
  
iii 
SAMENVATTING 
Magnetic Resonance Imaging is de laatste drie decennia een gevestigde waarde in 
de medische beeldvorming en diagnostiek geworden door zijn hoge resolutie en 
contrast. De relatief lage gevoeligheid is echter een groot nadeel. Het is mogelijk 
om complementaire informatie te bekomen wanneer MRI wordt gekoppeld met 
een veel gevoeligere techniek zoals optische beeldvorming. In deze verhandeling 
worden nieuwe multimodale contrast reagentia voor optische beeldvorming en 
beeldvorming door magnetische resonantie.  
 
Ten eerste worden de synthese en karakterisatie van twee DTPA gebaseerde 
heteropolymetallische metallostar-complexen toegelicht met de algemene 
formules (GdL1)3Ln, (GdL2)3Ln en (GdL3)3Ln. De synthese maakt gebruik van 
een recent ontwikkelde methode binnen onze groep om twee verschillende 
lanthanide(III)-ionen in een ditopisch ligand te complexeren. Hierbij zullen zowel 
gadolinium(III)-ionen, die nodig zijn voor het MRI contrast, en luminescerende 
lanthanide(III)-ionen worden gebruikt, met als resultaat een sterk paramagnetisch 
en luminescerend complex. Door de hogere energie van de aangeslagen toestand 
van L1 is dit ligand beter in staat om zijn energie naar het lanthanide ion over te 
brengen dan L2. Hierdoor zijn er lagere kwantumopbrengsten voor (GdL2)3Ln 
gemeten, 1.5%, 15.3%, en 0.8%, in vergelijking met de waarden voor (GdL1)3Ln 
9.8%, 30.9% en 1.2% voor respectievelijk Ln = Eu(III), Tb(III), Dy(III). NMRD 
metingen op het (GdL2)3Ln (Ln = Eu(III), Tb(III), Dy(III)) vertonen 
respectievelijke relaxiviteitswaarden (r1) van 24.27, 22.80 en 21.72 s-1mM-1 per 
metallostar-complex bij 310 K en 20 MHz. 
 
In een tweede aanpak worden de oppervlaktes van kleine monodisperse ijzeroxide 
nanopartikels covalent gebonden met nieuwe BODIPY derivaten door middel van 
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thiolene click-chemie gefunctionaliseerd. De fluorescentie-eigenschappen en 
levensvatbaarheid van cellen van de gemaakte nanopartikels werd bestudeerd. 
Sterke fluorescentie in water werd gemeten bij 538, 594 en 661 nm voor 
ijzeroxide nanopartikels met respectievelijk BDP1, BDP2 en BDP3. Uit de 
levensvatbaarheidstudies op verschillende cellijnen, rattumorcellen (AR42J) en 
menselijke eierstokkankercellen (SKOV3), werd geen acute toxiciteit 
waargenomen bij de gebruikte concentraties. De menselijke levercellen (GRX) 
werden enkel bij de hoogste concentraties (200 µg/ml) significant aangetast.  
 
Bij een derde aanpak werd een gadolinium(III)-DOTA complex gekoppeld aan 
een amino-BODIPY derivaat door middel van een cycloadditie gekatalyseerd door 
koper(I). Het amine wordt gesubstitueerd door een diazotransferreagens in een 
koperen buis door middel van een flow-reactie. Het gevormde azide wordt 
rechtstreeks gekoppeld met een alkyn aan het gadolinium(III)-DOTA in het bijzijn 
van natrium ascorbaat. Het resulterende complex bevat zowel een 
paramagnetische kern voor MRI en een sterk fluorescerende eenheid met het 
BODIPY-derivaat. Het gesynthetiseerde wateroplosbare complex geeft een intens 
emissiesignaal op 523 nm en absorptiemaximum bevindt zich bij 507 nm. De 
quantum yield in water van het complex bedraagt 83% en relaxiviteit gemeten bij 
310 K geeft 3.9 en 3.6 s-1mM-1 respectievelijk bij 20 en 60 MHz.  
 
In een laatste methode werd peptidechemie gebruikt om nieuwe DOTA-BODIPY 
derivaten te maken. Helaas werd het finaal product vernietigd bij het 
ontschermingsproces. Verder werd de synthese van twee La-DOTA chelaten met 
BODIPY-derivaten beschreven. De azide bevattende BODIPY-derivaten werden 
gereproduceerd uit de literatuur en door middel van koper(I)-gekatalyseerde 
cycloadditie aan La-DOTA-complex gekoppeld ter vorming van La-DOTA-BDP4 
en La-DOTA-BDP5. Deze wateroplosbare complexen vertonen fluorescentie bij 
508 en 510 nm respectievelijk met een kwantumopbrengst van 39% en 64%. De 
relaxiviteit van de complexen wordt geacht hetzelfde te zijn als overeenkomstige 
Gd-DOTA complexen. 
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PREFACE 
Most medical imaging techniques make use of specifically designed contrast 
agents (CAs) to optimize the recorded images. The combination of two medical 
imaging techniques would increase the information gained from an image but 
requires the development of new diagnostic modalities. This multimodal approach 
has already been successfully implemented in modern medical imaging. MRI 
excels in its spatial resolution but suffers from low sensitivity. Optical imaging 
(OI) on the other hand is a very sensitive technique, but lacks the tissue 
penetration and high spatial resolution. These techniques are especially interesting 
as they are both non-invasive and non-ionizing. Combination of two probes for 
both optical and magnetic resonance imaging into one molecule assures the same 
biodistribution and reduces the exposure of the body by two separate drugs. The 
design of the new contrast agents will incorporate an optical probe for OI and a 
paramagnetic centre for MRI in a single probe.  
In this PhD thesis the development of new bimodal MRI contrast agents via 
different approaches is highlighted and builds further on existing, commercially 
used CAs. Clinically used paramagnetic chelates of gadolinium(III) act as positive 
contrast agents, brightening the water rich regions of the image, thus enhancing 
the contrast. The reverse is true for negative contrast agents. Iron oxide 
nanoparticles are the clinically approved contributor to the latter group. New MRI 
instruments tend to operate at higher magnetic field as this improves the image 
quality and sensitivity. Current commercially available (positive) contrast agents 
lose their relaxivity efficiency at these higher fields, while negative contrast agents 
generally operate much better. By increasing the molecular weight, the increase of 
relaxivity at higher magnetic field strengths can be obtained. Another important 
factor to take into account is the emission wavelength of the optical probe. The 
best resolution in a human body is obtained between 665–900 nm, the optical 
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window of the body. Lanthanide(III) based systems are interesting as most of the 
ions emit within this region. In addition, the luminescent lifetimes of these ions 
are very long, which improves the signal to noise ratio. A promising class of 
organic luminophores are Boron-DIPYrromethene (BODIPY) dyes. These are 
small organic molecules with generally very high extinction coefficients, fairly 
sharp fluorescence peaks and high quantum yields. Furthermore the emission 
wavelength is tuneable by adding substituents on the BODIPY core. 
In this work the different approaches towards designing bimodal contrast agents 
are described. The first two chapters are introductory: chapter 1 presents the 
magnetic resonance and optical imaging, while chapter 2 goes deeper into the 
contrast agents used for MRI and describes also the scope of the PhD thesis. The 
compounds described in chapter 3 are potential bimodal positive contrast agents 
consisting of self-assembled metallostar complexes with an f-block element core 
and three peripheral Gd-DTPA moieties. The complexes contain aromatic organic 
structures which will act as an antenna for f-block luminescence and provides 
rigidity to effectively increase the rotational correlation time. In a second approach 
iron oxide nanoparticles (IONPs) are used as potential high field bimodal negative 
MRI CAs. Therefore three new BODIPY dyes are synthesized and covalently 
bound onto the IONPs surface. The design, fluorescent data and MRI response are 
highlighted in chapter 4. In a final approach, different BODIPY analogues are 
coupled to Gd-DOTA to obtain potential positive bimodal contrast agents. 
Different azide containing BODIPYs are synthesized and coupled via click 
chemistry. In chapter 5 the azide formation in a copper tube via a diazotransfer 
reaction is described. With the subsequent copper-mediated cycloaddition a new 
potential positive contrast agent is developed and its fluorescent and relaxometric 
data have been examined. Other methods for BODIPY synthesis, azide formation 
and coupling to a DOTA moiety are presented in chapter 6. 
 
 
 
CHAPTER 1 
Medical Imaging 
 
 
  
Medical Imaging| 
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1 History of medical imaging  
In late 1895, Wilhelm Conrad Roentgen experimented with a special tube and 
noticed a “new type of electromagnetic radiation”, now known as x-rays. This 
radiation could expose a film even when it was optically shielded. Not soon after, 
he took a picture of his wife’s hand and published the first medical image. In early 
1896 the clinical use of x-rays was established and since then a wide variety of 
different methods of radiography has been developed. In 1972 the first computed 
tomography (CT) scanner was produced by Godfrey Hounsfield. This technique 
uses mathematical methods to reconstruct an image.  
When Antoine Henri Becquerel discovered radioactivity in 1896, radionuclides 
were first used in cancer therapy. It was not until 1923, when George de Hevesy 
used radiotracers to study chemical processes. These molecules were radioactively 
labeled drugs that mimic biological compounds. In these early studies non-
imaging radiation detectors were used and only a rough idea of the amount of 
radiation could be obtained. The first imaging cameras were developed in 1949. 
The modern Anger scintillation camera was introduced by Hal Anger in 1952 and 
uses a collimator, a special absorbing crystal, and a series of photomultiplier tubes 
(PMTs).  
Not all medical imaging techniques use high energy radiation, other techniques 
such as ultrasonography and nuclear magnetic resonance use ultrasound or radio 
waves respectively. The former technique has its beginnings in World War I when 
navy sonar technology was being developed to detect submarines. The basic 
principle of ultrasonic imaging is fairly simple: a propagating wave partially 
reflects at the surface between different tissues. These reflections can be measured 
in function of time. When the velocity in these tissues is known, information about 
the position of the tissue is provided. Magnetic resonance imaging (MRI) is based 
on nuclear magnetic resonance (NMR) technique. The physical phenomenon of 
NMR has been reported by Bloch, Hansen, and Packard in 1946,1,2 but the 
application in medical imaging was realized by Lauterbur in 1973 when he made 
the first NMR image.3 P. Lauterbur and P. Mansfield received the Nobel Prize in 
medicine in 2003 for their discoveries concerning magnetic resonance imaging.4,5  
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2 Magnetic Resonance Imaging   
Magnetic resonance imaging does not make use of high energy radiation, which 
might be harmful to the human body. Basically, MRI measures the magnetic 
property of different tissues and provides a viable tool in diagnostics of the brain, 
torn ligaments and different types of cancers, to name a few. About 60% of the 
human’s body weight consists of water, and therefore the strongest MRI signal 
comes from water protons. The patient is put in a strong three-dimensional 
magnetic field, which is generated by a superconducting magnet that consists of 
wire coils through which a current is passed. The radio frequency (RF) coils will 
transmit and receive radio frequency waves into the patient’s body. (Figure 1.1) 
To ensure superconductivity, the coils are constantly cooled in liquid helium (T = 
4 K). Three smaller gradient magnets are used to generate a magnetic field 
gradient, so anatomical information can be obtained for every region of the human 
body. 
 
Figure 1.1. A schematic representation of the inside of an MRI 
scanner. The magnet with its gradient coils will ensure a 
gradient magnetic field around the patient. The RF coils are 
needed to transmit and receive radio frequency waves. † 
The differences between the intensities of tissues are due to variations in water 
density, proton relaxation times and water diffusion rates. Cancer cells generally 
have a higher water density than healthy cells. Another approach is making use of 
faster proton relaxation rates in fat than in bulk water. The image contrast can be 
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increased by the use of contrast agents, paramagnetic compounds which will 
increase the relaxation rates. The first contrast agents made use of the 
paramagnetic manganese(II) ion as its chloride salt or its complex with 
dipyridoxyl diphosphate.6,7 In the late 1990’s two Mn(II) contrast agents were 
approved for medical use, but are nowadays discontinued.8,9 The first contrast 
agent for medical use based on gadolinium(III) ion was approved in 1988. 
Nowadays Gd(III) type of probes are routinely used in MRI investigations.10,11 
Another type of existing medical contrast agent consists of superparamagnetic iron 
oxide nanoparticles (SPIONPs).12 
2.1 Magnetic Resonance Imaging: theory 
The next part will highlight some theoretical aspects of NMR to get an 
understanding on how an MRI machine works. In a first part a brief explanation of 
nuclear spin is presented and how it interacts with a magnetic field. Then the 
process of relaxivity is discussed, followed by the transformation from the signals 
into an image. 
Atoms consist of a positively charged nucleus surrounded by one or more 
electrons. This positive nucleus rotates around its axis, creating a magnetic dipole 
with a magnetic moment (µ). The angular moment of this magnetic moment can 
be represented by spin vector. In quantum physics this spin angular momentum is 
described by a spin quantum number (I). When an external magnetic field (B0) is 
applied to the nuclei, bulk magnetization is developed in the sample.  
The 1H atom (proton) has a natural abundance of 99.9885% and a spin quantum 
number of ½.Without an external field the spins are randomly oriented (Figure 
1.2A) and no net magnetization is observed. Whenever these nuclei are put in a 
magnetic field they will align preferably towards the external magnetic field 
vector (B0) and a net magnetization vector (M) along the external field is 
observed. In a magnetic field the spin will start to make a precessing motion 
around the magnetic field vector with a specific angular frequency, called the 
Larmor frequency (Figure 1.2B).  
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Figure 1.2. A) Proton vectors in the absence of a magnetic field are pointing in a 
random position. B) Proton vectors in the presence of a magnetic field B0 have a 
preference to align towards the external field, forming a net magnetization vector (M) 
along the external field (large arrow). All spins have a precessing motion around the 
external magnetic field (figure based on ref 13). 
When in addition to the magnetic field a 90° radio frequency pulse is applied, the 
net magnetization vector will be perturbed into the xy-plane and all protons will 
precess in phase. After the RF pulse two different processes will take place 
simultaneously. The longitudinal relaxation process comprises the recovery of the 
net magnetization vector along the direction of the external magnetic field (Figure 
1.3), and the energy is released to the surroundings or the lattice. It is therefore 
called longitudinal or spin-lattice relaxation and is characterized by the 
longitudinal relaxation time (T1). The inverse is called the relaxation rate R1.  
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Figure 1.3. Longitudinal relaxation process: after the 90° RF pulse stops, the 
net magnetization vector (M) returns back along the external magnetic field  
(z-axis). 
The transverse relaxation process describes the loss of phase coherence. In other 
words, the protons will no longer precess together due to small differences in 
Larmor frequencies (Figure 1.4). Another factor is energy exchange between two 
spins. No energy is lost during this transition, but dephasing of spins will take 
place. The exponential decay of the signal in time is called free induction decay 
(FID). The process is characterized by the transverse relaxation time (T2) and its 
inverse is the transverse relaxation rate R2. 
 
Figure 1.4. Transverse relaxation process: the different spin vectors will rotate around 
the z-axis in the xy-plane at different speeds due to inhomogeneities in the local 
magnetic field. Therefore they will start to dephase and in the end no spin vector will 
point in the same direction. 
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All contrast agents have an effect on both longitudinal and transverse relaxation 
processes. The effect that is influenced the most is used to classify the CAs into 
categories. Contrast agents containing gadolinium(III) will affect the longitudinal 
relaxation time (T1) more. These CAs will increase the intensity of water 
containing parts of the body and are called positive contrast agents. A darkening 
of the image is also possible and is caused by negative contrast agents. They 
decrease the transverse relaxation time (T2). Iron oxide nanoparticles are part of 
this category. They introduce a large inhomogeneity in the local magnetic field 
which increases the loss of phase coherence, and decrease the signal intensity. 
2.2 Magnetic Resonance Imaging: practice 
The following segment gives insight in how the signals are processed into a 3D 
image. We get an understanding of the spin behavior and its time dependency 
from the relaxation processes. A simple pulse program used in MRI is spin echo 
sequence (Figure 1.5). After the 90° pulse, a second 180° pulse is applied to 
restore the phase coherence between the spins and an echo is observed. The time 
between the 90° pulse and the spin echo is called the echo time (TE). It is a 
parameter which can be altered depending on the 180° pulse. The timing will have 
an effect on the spin echo signal, thus the image. The time between consecutive 
90° pulses is called the repetition time (TR). 
 
Figure 1.5. Spin echo sequence with the time between the 90° pulse 
and the spin echo, TE, and the time between 90° pulses, TR, two 
important parameters to obtain a 3D MRI image.14 
By changing the parameters TE and TR, the MRI operator can choose three 
different types of images: proton density, T1- and T2-weighted (Figure 1.6). In 
general a proton density weighted images are obtained by a long TR and either no 
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or a small TE. It will generate an image with clear bright spots where proton rich 
tissues are located, because one would get a maximum signal from tissues with a 
minimum in transverse decay. In a T1-weighted measurement both TE and TR will 
be relative small. The same reason for a short TE applies here as well, minimizing 
transverse relaxivity. TR is reasonably short to get a tissue effect. For example, 
take two different tissues from the brain with respectively a short and a long T1: 
fat and cerebrospinal fluid (CSF). At the TR, the net magnetization of fat will have 
a much higher value than CSF. Thus the contribution of M being flipped into the 
xy-plane of CSF at TR is small, therefore the overall signal will be small and the 
image appears dark. The reverse is true for fat tissue, which will appear bright. 
Mostly the TR will be chosen to be approximately the T1 value of the tissue with 
the smallest T1. The image contrast becomes dependents on the T1 relaxation 
process of the tissues. T2-weighted images generally have a long TR to avoid T1 
effects, and relative long TE to ensure dephasing. Generally, the TE value will 
more or less be equal to the T2 of the examined tissues. 
 
Figure 1.6. The MRI operator can choose the contrast of the different 
tissues observed in the image by changing the echo time (TE) and 
repetition time (TR). The different images are classified as: proton 
density (PD), T1-weighted, and T2-weighted.14 
As mentioned above, to obtain a 3D image, MRI uses three gradient magnetic 
fields to give extra information to the NMR signal. The gradient along the 
patient’s body (z-axis) is used for the slice selection. The other gradients are 
frequency encoding (x-axis) and phase encoding (y-axis) gradients which 
spatially separate the signals within the slice. With this information, a computer 
can calculate a 3D image. MRI is a very strong technique which can give 
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anatomical and pathological information about the whole human body as is shown 
in Figure 1.7. 
 
Figure 1.7. A full body MRI scan (right) and angiography (right) 
taken with a 3T apparatus. † 
3 Optical imaging 
In the last decades numerous attempts have been made to design optical imaging 
applications for medical diagnostics. A first attempt was done by Cutler in 1929, 
who illuminated a female breast with a bright light source in a darkened room. 
Despite attempts to improve the illumination by employing NIR sources and 
detectors, clinical utility remained severely limited.15 Although the high sensitivity 
of the technique makes it very interesting, major drawbacks in penetration depth 
and image reconstruction due to scattering, reflectance, absorbance and 
fluorescence of photons by the biological tissues are encountered.16 Only a few 
optical modalities are currently used in medicine.17,18  
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Clinical or pathological information could be obtained from tissue diagnostics 
while limiting the problem of tissue penetration such as “optical biopsy”. In these 
samples reflectance and fluorescence lifetime imaging microscopy (FLIM) can 
provide functional information, confocal microscopy (CM) and multiphoton 
fluorescence microscopy (MFM) resolves cellular morphology, optical coherence 
tomography (OCT) provides highly resolved cross-sectional imaging within the 
tissue.19 
Fluorescence lifetime microscopy can reduce the scattering effect as it measures 
the lifetime of the fluorophores signal rather than the intensity. The setup consists 
of a pulsed diode laser and the decay is measured by a detector. FLIM is an 
interesting technique to use for imaging of the brain, as the brain scatters light 
strongly. 
Optical coherence tomography works similar to echography, but the image is 
reconstructed from scattered light instead of ultrasound waves. Due to the shorter 
wavelength of light, high resolution images (≤ µm) are possible. A typical setup 
contains a light source which illuminates a sample, usually a diode, and a detector 
which collects the scattered light. OCT can be compared to a microscope without 
the need to dissect the sample and reveals subsurface (~ mm) information. OCT 
finds its uses in retina malfunctions and diagnostics of nerve, vein and heart 
problems. 
Confocal microscopy offers an improved spatial resolution compared to 
conventional microscopy. The light source, usually a laser, is focused at a specific 
point within the tissue. This focal point can be scanned by a mirror system and is 
imaged onto a pinhole in front of the detection system (Figure 1.8). The pinhole 
rejects photons originating from outside the focal plane thus improving the spatial 
resolution. The two main in vivo clinical applications are in dermatology and 
ophthalmology. The contrast of melanin is used to distinguish between normal and 
abnormal tissue. A wide range of corneal diseases can be detected using this 
technique.  
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Figure 1.8. Confocal microscopy. The pinhole is scanned sideways, up and down to 
gather images from different focal planes resulting in a three-dimensional image of the 
specimen. Out-of-focus light rays are blocked to improve the spatial resolution. 
 
Multiphoton fluorescence microscopy is similar to confocal microscopy.20 The 
generated images of both techniques come from focused laser beams which scan 
in a raster pattern. Both have an optical sectioning effect, where a suitably 
designed microscope can produce images of focal planes deep within a thick 
sample. Unlike confocal microscopes, a multiphoton microscope does not contain 
pinhole apertures. It uses a pulsed long-wavelength laser to excite fluorophores 
within the specimen which absorb the energy from two long-wavelength photons 
that arrive simultaneously to excite an electron into a higher energy state. These 
longer wavelengths, typically in the infra-red region, are well-suited to use in vivo 
as they cause less damage and have greater penetration depths than short-
wavelength lasers.  
 
 
 
 
Medical Imaging| 
 
14 
 
Figure 1.9. (a) Single-photon excitation of fluorescein (488 nm). (b) Two-photon 
excitation using focused femtosecond pulses (960 nm).20 
Next to the mentioned techniques, optical imaging can be a viable tool during 
surgery. A metabolic precursor can be injected into the patient prior to surgery. 5-
ALA is known to accumulate fluorescent porphyrins in malignant glioma 
tissues.21 During the operation, the surgeon can switch between conventional to 
violet-blue illumination (Figure 1.10). Necrotic tumor displays no or only 
inhomogeneous red fluorescence, viable tumor tissue is distinguished by its deep 
red fluorescence (solid) and pink fluorescence is encountered between the 
fluorescent tumor and non-fluorescent blue brain tissue (vague).22 
 
Figure 1.10. Necrotic tumor displayes no red fluorescence (necrosis), viable tumor 
tissue has deep red fluorescence (solid) and between fluorescent tumor and non-
fluorescent blue brain tissue a pink fluorescence was encountered (vague).22 
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† Illustrations courtesy of Siemens Healthcare GmbH and can be found in their 
product brochures of MAGNETOM series MRI instruments or their website: 
http://www.healthcare.siemens.com/magnetic-resonance-imaging 
  
CHAPTER 2 
Contrast Agents for  
Magnetic Resonance Imaging 
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1 Relaxivity 
As MRI is based on proton relaxation, an important attribute of all contrast agents 
is its relaxivity. Relaxivity is defined as the ability of a 1 mM concentration of a 
contrast agent (CA) to enhance the water relaxation rate. Already in the middle of 
the twentieth century the physical phenomenon of relaxivity was explored, leading 
to the Solomon, Bloembergen, and Morgan (SBM) theory.1–4  
Both the longitudinal (1/T1) and transverse (1/T2) relaxation rates increase when 
introducing a paramagnetic nucleus to a solvent. The observed relaxation rate 
(1/Ti,obs) is defined as the sum of a diamagnetic term (1/Ti,d), corresponding to the 
relaxation rate of the solvent in absence of a paramagnetic centre, and a 
paramagnetic term (1/Ti,p), which is the enhancement of the relaxation rate caused 
by the paramagnetic centre:5 
1Ti,obs = 1Ti,d + 1Ti,p (i = 1, 2) (eq. 2.1) 
The paramagnetic contribution is linearly proportional to the concentration of the 
added contrast agent (in [Gd]). Substitution in eq. 2.1 gives: 
1Ti,obs = 1Ti,d + ri[Gd] (i = 1, 2) (eq. 2.2) 
The parameter ri is called the proton relaxivity expressed in its unity s-1mM-1. It is 
a factor referring to the efficiency of a contrast agent to enhance the relaxation rate 
of water molecules. 
A dipole-dipole interaction between the proton spins and the fluctuating local field 
caused by the unpaired electrons of the Gd(III) is the source of the enhanced water 
proton relaxation. The paramagnetic enhancement can be split into two main 
contributors. The first type is inner sphere contribution, resulting from water 
molecules bound in the first coordination sphere of the gadolinium(III) centre 
which are in constant exchange with the bulk solvent molecules. A second type is 
the outer sphere contribution which is due to random translational diffusion of the 
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bulk water molecules that will experience a paramagnetic effect. Water molecules 
bound via a hydrogen bond are taken into account as second sphere effects.6 The 
total paramagnetic relaxation can be described by eq. 2.3, or expressed in term of 
relaxivities by eq. 2.4.  
1Ti,p = � 1Ti,p�IS + � 1Ti,p�OS (i = 1, 2) (eq. 2.3) 
ri = riIS + riOS (i = 1, 2) (eq. 2.4) 
The design of new contrast agents mainly focuses on alteration of the inner sphere 
longitudinal relaxivity, as they are well studied and more easily altered than the 
outer sphere parameters.  
2 Inner sphere proton relaxivity 
The longitudinal relaxation rate of the bulk solvent nuclei is given by eq. 2.5:7 
�
1T1�IS =  q × PmT1m + τM (eq. 2.5) 
Where q is the amount of water molecules bound directly to the paramagnetic 
centre, Pm the mole fraction of bound solvent molecules, 1/T1m the relaxation rate 
of the coordinated water molecule and τM the residence time (= 1/kex) of solvent 
molecules in the complex. If the water exchange is fast (τM << T1m), the 
enhancement of relaxivity is proportional to the relaxation rate of the bound 
nuclei.8 
According to the modified Solomon-Bloembergen equations, the relaxation 
mechanism of the inner sphere molecules can be subdivided in a dipole-dipole 
(DD) and a scalar (SC) mechanism: 
1T𝑖,𝑝 = 1TiDD +  1TiSC (i = 1, 2) (eq. 2.6) 
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The dipole-dipole interactions are considered a ‘through space’ contribution and 
are determined by the reorientation of the nuclear spin – electron spin vector. 
Scalar interactions are considered ‘through bound’ contributions and only depend 
on the electron spin relaxation and the water exchange rate. As the contribution of 
the scalar term is considerable smaller (~ 6 times) than the dipole-dipole 
interactions, this term is mostly neglected in the optimization of the relaxivity. The 
dipole-dipole term can be considered:   
1TiDD =  215 γI2g2µB2S(S + 1)r6 � 3τc11 + ωI2τc12 + 7τc21 + ωS2τc22 � (eq. 2.7) 
where γI is the nuclear gyromagnetic ratio (42.57 MHz/T for 1H), g is the electron 
g factor, µB is the Bohr magneton, S is the spin quantum number (S=7/2 for Gd3+), 
r is the distance between the paramagnetic centre and the coordinated water 
molecules, ωI and ωS the nuclear and electron Larmor frequencies respectively, 
and τci the dipole-dipole correlation times. From eq. 2.7 it is clear that the distance 
to the paramagnetic centre has a large impact on the proton relaxation. The 
correlation times τci are characteristic for the relaxation process and are depicted 
as: 
1
𝜏𝑐𝑖
= 1
𝜏𝑅
+ 1
𝜏𝑀
+ 1
𝑇𝑖𝑒
 (i = 1, 2) (eq. 2.8) 
where τR is the rotational correlation time, or more precisely, the reorientation 
correlation time of the metal to proton vector. The τM is the residence time of the 
water molecules bound to the paramagnetic centre, and Tie is the electron spin 
relaxation of the metal ion.  
The important factors for a good ligand design are depicted in Figure 2.1. From 
eq. 2.5 it is shown that if the overall correlation time τci increases, the longitudinal 
relaxation time (1/T1) will be enhanced. If the residence time of the water 
molecules is rather long (T1m << τM), this parameter will be the limiting factor for 
proton relaxivity. In the reverse case (τM << T1m), the overall correlation time will 
depend on the relaxation rate of the coordinated water molecules (T1m), which is 
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determined by τR, τM, and Tie. The challenge in order to obtain the highest 
relaxivity is that all factors, τR, τM, and Tie, must be simultaneously optimized.  
 
Figure 2.1. Schematic representation of the different physical 
parameters influencing the relaxation efficiency of MRI contrast 
agents. 
2.1 Positive contrast agents 
The positive contrast agents are mainly governed by gadolinium containing 
chelates. Gadolinium is a chemical element with atomic number 64 and part of the 
lanthanide series in the periodic table of the elements. The lanthanide series have 
high coordination numbers (CN), descending from ten or nine for the light ions, to 
eight or seven for the heavy trivalent metal ions. Gadolinium has a CN = 8-9, 
adopts the +3 oxidation state, has seven unpaired electrons and a large magnetic 
moment (7.94 µB). Gadolinium(III) has relatively long electron relaxation times 
due to its symmetric 8S7/2 ground state.5 Free gadolinium(III) ions are toxic to 
living animals (LD50 = 0.2 mmol·kg-1 in micea).7 As the general dose of CA 
administered is 0.1-0.3 mmol per kg body weight, highly thermodynamically 
                                                          
a LD50 is a standard measurement of acute toxicity representing the individual dose 
required to kill 50% of a population of test animals. 
Contrast Agents for Magnetic Resonance Imaging| 
 
22 
stable and high kinetically inert chelates are necessary.9 Two most commonly used 
ligands are the acyclic diethylenetriaminepentaacetic acid (DTPA) and the cyclic 
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA). These ligands 
are eight-fold coordinated to gadolinium(III), ensuring a stable complex of log K 
= 22.5 and 25.3 for DTPA and DOTA respectively.8 In the past decades, a couple 
of their analogues have been also approved for medical use (Figure 2.2).10 All 
commercially available CAs have an 8-fold coordination with their ligand, 
allowing binding of one water molecule directly to the metallic centre while 
assuring stable complexes. 
The gadolinium(III) based CAs passively distribute in the extracellular space and 
exhibit no specific tissue accumulation, do not penetrate the blood-brain barrier, 
and are completely and quickly excreted via the kidneys. Multihance® and to a 
lesser extend Eovist®, are taken up by the hepatocytes in the liver and excreted 
into the bile. This uptake allows for organ specific diagnosis of a variety of liver 
lesions and provides an additional excretion pathway. Ablavar® is a blood pool 
agent due to the strong but reversible binding to serum albumin, a common protein 
in the blood, which leads to a very slow but complete renal elimination.11  
2.2 Negative contrast agents 
Within the group of negative contrast agents, iron oxide NPs are the main 
contributor. Two groups exist: the superparamagnetic iron oxide (SPIO) and the 
ultrasmall superparamagnetic iron oxide (USPIO). They are superparamagnetic 
and induce inhomogeneities in the local magnetic field, increasing the transverse 
relaxation time (T2), thus decreasing the intensity of the MR signal. The iron oxide 
NPs are generally coated with organic molecules, such as dextran, 
carboxydextran, or citrate, to increase their dispersibility and biocompatibility in 
solution. In the past, several iron oxide NPs were commercially and clinically 
investigated, including: ferumoxides (Endorem®/Feridex®), ferrumoxtran-10 
(Sineram®/Combidex®), ferucarbotran (Resovist®/Cliavist®) and ferumoxsil 
(Lumirem®/GastroMARK®). All but the latter are currently discontinued for a 
variety of reasons, one of which is to many false positives.12 
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Figure 2.2. Clinically approved gadolinium(III) contrast agents. The water molecule is 
omitted for clarity. (figure based on ref. 8) 
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3 Optimization of positive contrast agents 
Due to extensive research, a lot of insight is gained into the parameters governing 
relaxivity of contrast agents.8,13–20 In the next part these parameters are discussed 
into more detail. 
3.1 Hydration number, q 
Increasing the amount of water molecules directly bound to the paramagnetic 
centre will drastically increase the overall proton relaxivity. However, all 
commercial contrast agents based on DTPA or DOTA have a hydration number of 
one (q = 1). Although removing an acetic acid arm from DOTA would free up an 
extra space for an additional water molecule, the thermodynamic stability of the 
complex will decrease by several orders.21 Furthermore, the relaxivity is easily 
quenched by substitution of water by small molecules like carboxylic or amino 
acids, thus decreasing the efficiency of the CA.22 The latter problem can be 
circumvented by using ligands such as DTTA,23 AAZTA24 or HOPO25 (Figure 
2.3). These ligands have the ability to form Gd(III) complexes with two water 
molecules in the first coordination sphere, but are less affected by small molecules 
in solution. Although these ligands will form thermodynamically stable chelates 
with gadolinium(III), they suffer from low kinetic stability. Generally, increasing 
hydration number is not considered a viable way to increase the relaxivity. 
 
Figure 2.3. Structures of DTTA, AAZTA and HOPO ligand with a hydration number 
with q = 2. The water molecules are omitted for clarity. 
| Chapter 2 
 
25 
3.2 Residence time of the water molecule, 𝛕𝐌 
Another important factor is the residence time of the water molecules in the 
complex, τM, as it defines the efficiency in transmitting the relaxivity to the bulk 
solvent. Ideally the water exchange should be fast (10-30 ns) to increase 
relaxivities of the contrast agents at present magnetic fields (60 MHz or 1.5 T).26 
However, at higher magnetic field strengths shorter values of τM are necessary (1-
10 ns). The value of τM mainly depends on the charge, solvent accessibility, steric 
hindrance around the binding site, and mechanism of water exchange of the 
complex. Negatively charged species will force water molecules to leave and 
shorter τM (~ 50-300 ns) are obtained in comparison to neutral and positive 
charged species. Transformation of a carboxylic acid group of both DTPA and 
DOTA like ligands into an amide functionality will increase τM, as the amide-
oxygen distance is longer and induces less sterical hindrance. Alteration of the 
binding side, such as adding hydrophilic or hydrophobic groups, can influence the 
access of bulk water molecules to the binding site and thus change τM.27 For 
example adding a bulkier group such as phosphorus containing side arms will 
decrease the residence time of water.28,29 According to the SBM theory the optimal 
value for τM is closely related to the rotational correlation time τR. 
3.3 Rotational correlation time, 𝛕𝐑 
The molecular tumbling rate or rotational correlation time τR is the easiest 
parameter to adjust and this approach is applied in most cases to increase the 
relaxivity, especially at higher magnetic field strengths. For spherical particles an 
idea of the rotational correlation time can be given by the Debye-Stokes equation: 
τ𝑅 = 4𝜋𝜂𝑎33𝑘𝑏𝑇  (eq. 2.9) 
From eq. 2.9 it is clear that if the molecular radius a and the viscosity η are known 
the correlation time can be calculated. τR of commercial contrast agents is in the 
range of 0.1 ns. Relaxivity of these small complexes is efficient at lower magnetic 
field strengths and decreases at higher magnetic field strengths. To increase the 
signal to noise ratio of images, novel generation of MRI instruments will likely 
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operate at higher magnetic fields (Figure 2.4). For such purposes new contrast 
agents should be developed, because commercial CAs lose their efficacy at higher 
fields. The different employed strategies are all conceptually the same and rely on 
increasing the molecular weight, thus increasing the rotational correlation time. 
Up to now, a lot of effort has already been done to increase this parameter.18,19 
 
Figure 2.4. The difference between an image taken by a 3 Tesla (left)  
and a 7 Tesla (right) MRI apparatus. † 
A first approach is non-covalent binding to proteins, such as the blood pool 
abundant human serum albumin (HSA) protein. Contrast agents for angiography, 
such as Ablavar®, have an apolar tail which reversibly interacts with HSA.30–34 
Several other reported CAs can interact with different types of proteins.14,35 Blood 
pool contrast agents show an increased relaxivity by effectively increasing τR.36  
The molecular weight of monomeric Gd(III) chelates can also be increased by 
conjugation to macromolecules. Hyperbranched polymers are well suited for the 
application, as the rotational dynamics is in between linear polymers (fast rotation) 
and star polymers (poor water accessibility).37 Dendrimers are well-suited 
scaffolds for CAs with their well-defined architectures, multivalent surfaces, and 
nanoscale sizes. Numerous types have already been synthesized and reported.38 
Different applications can be selected when using different generations of 
dendrimers. In general, a size range of 3–6 nm could potentially be suitable for 
functional renal imaging, while those with a size range of 7–12 nm could be used 
for blood pool contrast enhancement.39,40  
A third approach incorporates long alkyl chains into the CAs structure to form 
micelles or liposomes. These aggregates form due to hydrophobic interactions of 
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the lipid tails, while the hydrophilic parts will face towards the bulky water. To 
obtain monodisperse and stable structures, cholesterol or phospholipids are added. 
Several such structures have been successfully synthesized during the last 
decade.41–43 Most recently the focus has shifted towards adding two alkyl chains to 
the CAs scaffold, which locks the Gd(III) chelate in place, limiting internal 
movement and increasing the overall relaxivity.44–46  
High relaxivities can be obtained by increasing the amount of Gd(III) per volume, 
for instance by fixating the paramagnetic ion onto nanoparticles. Gold 
nanoparticles can easily be coated with thiol containing moieties, examples of 2-3 
nm sized NPs with DTPA47,48 and DTTA are known.49 Possible CAs can be 
obtained by encapsulating Gd(III) ions in zeolites, such as GdNaY. Unfortunately 
the efficiency of these zeolites is low due to the slow diffusion of water 
molecules.50 Alternatives are silica based mesoporous nanoparticles, which show 
relaxivities as high as 11000 s-1mM-1 per nanoparticle.51 Another approach is ultra 
small nanocrystals made out of Gd2O3 capped with diethylene glycol for 
stability.52,53  
A subtle approach to increase τR is the self assembly of rigid heterometallic or 
metallostar complexes.54 This supramolecular approach has already been 
explored by our group. In vivo evaluation of a tetrametallic self-assembled 
complex of three phenantroline-substituted Gd-DTPA moieties present around one 
iron(II) ion, indicated potential enhancement in organs such as the liver.55 A linear 
relationship between the relaxivity and the molecular mass of a copper 
metallocrown complex with a gadolinium complex derived from alpha-
aminohydroxamic acid could be observed.56 
Despite the efforts of increasing the rotational correlation time of the CA, the 
theoretical maximum has not yet been achieved.13 The main cause is the local 
motion of gadolinium(III) chelates. Careful attention should be paid in regards to 
the flexibility of linker groups. By better fixation of the paramagnetic ion to the 
targets, the internal rotation can be reduced, for example by multilocus binding to 
micelles, liposomes or proteins. 
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3.4 Other parameters  
Theoretically one could increase the relaxivity by decreasing the distance 
between the bound water and the paramagnetic centre, because of the 1/r6 
relationship of the dipole-dipole interaction. Practically the distance for 8- to 9-
coordinated Gd(III) complexes ranges between 3.0 and 3.2 Å, and is difficult to 
alter.57 This distance can be measured by neutron diffraction on single crystals or 
by isotopic exchange.  
According to eq. 2.3 the overall relaxivity is given by inner and outer sphere 
contributions. The latter arises from random movement of the bulk solvent 
molecules around the paramagnetic centre. When the gadolinium(III) complex and 
water molecules are considered as hard spheres, the interaction between the 
Gd(III) electron spin and the proton nuclear spins can be described as a dipolar 
intermolecular interaction. At the magnetic fields of interest, the outer sphere 
contribution depends primarily on the distance of closest approach between the 
paramagnetic centre and the water proton (a), and the relative diffusion coefficient 
of solute and solvent (D).6 The diffusional correlation time can be expressed as 
τD = a2 D⁄ . Change of the outer sphere term is difficult as the distance of the 
closest approach remains the same (3.5–3.6 Å). The relative translational diffusion 
is set at a value close to the water diffusion rate (~3·10-9 m2s-1), which remains 
unchanged as well.58 Second sphere contributions can be enforced by interaction 
of bulk water molecules to functional groups. This effect is generally not 
considered separately, but included in the outer sphere term. 
The electron relaxation (Tie) for gadolinium(III) complexes is a magnetic field-
dependent phenomenon. Relative long relaxation times are observed for 
symmetric complexes such as Gd-DOTA. At low fields (< 0.1 Tesla) the 
electronic relaxation is fast and contributes to τc (eq. 2.8). The effect decreases at 
higher field strengths, when the rotational correlation time τR becomes the 
dominant factor. Usually the electron relaxation is not considered when designing 
new contrast agents. 
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3.5 NMRD profiles  
The magnetic field dependency of the longitudinal relaxivity r1 of a contrast agent 
can be determined by a technique called nuclear magnetic resonance dispersion 
(NMRD) and is measured by a fast field cycling NMR relaxometer. In this 
technique the magnetic field strength is adjusted from 0.25 mT to 1 T and the 
relaxivity increase is expressed as a logarithmic scale of units in Tesla or proton 
Larmor frequency (0.01–40 MHz). Assuming the SBM equations are valid the 
experimental data can be fitted to gain insight into the physicochemical 
parameters. The fitting of the data remains challenging as there are several 
parameters to be calculated simultaneously. Some of the parameters are fixed by 
measuring them via other techniques, such as τM, which can be estimated by 17O-
NMR, lifetime measurements which allows determination of the hydration 
number, or are based on literature values.7 Depending on the structure, inner-, 
outer-, and second-sphere contributions can have large effects on the relaxivity. 
Only the inner- and outer-sphere are mostly considered for monomeric 
gadolinium(III) complexes. The relaxivity of negative contrast agents, such as 
SPIO and USPIO particles, only depends on outer-sphere relaxivity and are 
governed by different parameters.59,60  
 
Figure 2.5. 1H NMRD plot of simulations of relaxivity as a function of 
proton Larmor frequency. The gray area shows the range of magnetic 
fields currently used for medical imaging.8 
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3.6 Safety of contrast agents 
A first parameter which is important when designing CAs is thermodynamical 
stability. The eight-fold coordination of gadolinium(III) of the commercial 
chelates ensure thermodynamically stable complexes, although modifications of 
the pendant arms can have a huge effect on this stability. Introducing two amide 
bonds in the DTPA scaffold (Omniscan®) results in less stable complexes (log K = 
15-19).9 As free gadolinium(III) is very toxic, high stability is necessary. 
Although complexes can be very thermodynamically stable, the metal ion can still 
be replaced by a different metal ion, resulting in a process that is called 
transmetallation. A second parameter in CA safety is therefore the kinetic stability 
of the Gd(III) complexes, which is related to the ability to withstand 
transmetallation by other metal ions, foremost Cu(II) and Zn(II). These metals are 
present in the human blood serum in sufficiently high concentrations and are able 
to compete with lanthanide binding in DTPA and DOTA. To test the kinetic 
stability, the relaxivity of an aqueous solution of Gd(III) complex in a phosphate 
buffer is examined. If Gd(III) would be released, insoluble GdPO4 salt will form 
resulting in relaxivity decrease. DOTA complexes are generally less affected by 
transmetallation than the acyclic DTPA derivatives.8 
Although the contrast agents that are currently in clinical use are considered safe, 
in 1997 cases of nephrogenic systemic fibrosis (NSF) were found in some patients 
with kidney failure. This is a severe condition which forms fibrosis, formation of 
excess connective tissue of skin, joints, eyes, and internal organs. In 2006 the link 
with Gd(III)-containing CA was discovered,61 and consequently the European 
Medicines Agency has issued some regulations to minimize the risk of NSF.62 
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4 Multimodal approach to contrast agents 
MRI is known for its high spatial resolution and high tissue penetration. 
Unfortunately this technique suffers from a low sensitivity. Sensitivity and image 
quality could be improved by operating at higher magnetic field strengths. More 
information from an image can also be obtained by coupling a complementary 
technique to MRI. Such a viable technique could be optical imaging (OI), as this 
technique excels at its sensitivity and offers fairly good resolution, but suffers 
from low tissue penetration. A tradeoff between tissue penetration and image 
resolution for in vivo imaging can be made in the optical imaging window from 
665 to 900 nm.63 In this region the extinction coefficients of the main sources of 
absorption, hemoglobin, deoxyhemoglobin, and water, are at their minimum. 
Combining two probes into one molecule would assure the same biodistribution. 
Choosing the right optical probe is paramount and many fluorescent probes have 
already been suggested.64 The luminescent probes vary from fluorescent 
macromolecules such as proteins or dendrimers, to organic dyes, fluorescent 
nanoparticles and d- or f-block elements.  
 
Figure 2.6. An optical window for in vivo imaging: an optimal tradeoff between image 
resolution and tissue penetration between 665 and 900 nm is found.65 
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4.1 Fluorescent macromolecules 
Numerous types of fluorescent dendrimers have been synthesized and 
reported.38,39 The tree-like dendrimers with a well-defined three-dimensional 
architecture have surface functional groups which can be modified with a variety 
of fluorescent probes enabling many different biological applications.38 Various 
kinds of bright luminescent proteins have been developed and have been used 
excessively in the visualization of functional processes inside animals and 
plants.66,67 Recently fluorescent NIR emitting conjugated polymers have been 
reported.68  
 
Figure 2.7. Fifth generation dendrimers are crosslinkeded with PEG 
chains. These dendrimeric nanoclusters are further functionalized 
with Gd-DTPA, fluorescent dye and folic acid.38   
4.2 Fluorescent nanoparticles 
Spherical nanosized semiconductors called quantum dots (QDs) are 
photochemical stable nanoclusters of 2–10 nm. They exhibit a narrow symmetrical 
fluorescence spectrum and very broad excitation spectra suitable for simultaneous 
multicolor detection.69 QDs are used in vivo for biological and biochemical 
research. The main concern is their toxicity, because most QDs consist of a Cd/Se 
core – ZnS shell or Cd/Te core-only clusters. The cytotoxic cadmium can leak out 
of the nanocrystal. Potentially less toxic alternatives are InP, InGaP, CuInS2 and 
AgInS2.70 
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Upconverting NPs are inorganic nanoparticles doped with f-elements in which a 
continuous absorption of two low-energy photons leads to the emission of a 
higher-energy photon.71 As this is a nonlinear process, the autofluorescence in bio-
imaging is eliminated. The core nanoparticle could consist of a NaGdF4 core 
doped with a small amount of Yb(III) and Tm(III) synthesized via thermal 
decomposition. Bright luminescence of 800 nm is obtained when illuminating the 
samples with a low intense NIR diode laser. Coating the surface with Gd(III) 
chelates a potential bimodal contrast agent can be formed.72 
4.3 Organic dyes 
A rather straightforward approach to develop bimodal contrast agents is the 
covalent attachment of organic fluorophores. Well-known groups of dyes which 
emit beyond 500 nm are fluoresceins, rhodamines, cyanines and 4,4-difluoro-4-
bora-3a,4a-diaza-s-indacene (BODIPY).73 These organic dyes can be altered to 
emit in the NIR region to obtain a better in vivo image quality.  
The name BODIPY is derived from BOron DIPYrromethene and the first 
BODIPY was synthesized by Treibs and Kreuzer in 1968.74 It was only until the 
90’s that the BODIPY dyes began to attract the attention of biochemists and 
biologists as a new candidate for fluorescence markers. 
 
Figure 2.8. The general structure of the BODIPY-core. 
The BODIPY dyes are currently used in a variety of applications such as 
biological labels and probes,75–77 fluorescent probes,78 laser dyes,79,80 light 
emitting diodes,81 solar cells,82,83 and potential sensitizers in photodynamic 
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therapy.84,85 The main characteristics of this class of organic dyes are very high 
extinction coefficients, fairly sharp fluorescence peaks, negligible triplet-state 
formation, and high quantum yields, even in water. The core is fairly stable under 
physiological conditions and relatively insensitive to the environment. The 
emission wavelength is tunable by modification of the BODIPY core.86,87 The 8-
substituted BODIPY dyes can easily be synthesized via condensation of acyl 
chlorides with pyrroles, followed by complexation with BF3·Et2O in the presence 
of a base. In 2010 Bernhard et al. synthesized the first BODIPY-DOTA derivative 
to be used as a bimodal contrast agent for MRI-PET.88 Although BODIPYs are 
versatile compounds with good optical properties, their use in developing bimodal 
contrast agents remain scarce.88–91 The main disadvantage for biological 
applications is the hydrophobic nature of the BODIPY core.  
4.4 Metal containing luminophores 
Ditopic ligands with an affinity to transition metals can form self-assembled 
luminescent heteropolymetallic complexes. If one moiety is coordinated with 
gadolinium(III) these assemblies can be used as bimodal contrast agents for MRI 
and optical imaging. This approach was used by Faulkner et al., 92 who reported a 
Gd-DOTA coupled to rhenium(I) complex emitting a red luminescence. 
Alternatively, Gd-DTPA with a variety of metal assemblies are known. Some 
examples are titanium(IV) catecholate93 or aluminium(III) 8-hydroquinoline94  
cores for green emission. Red emission can be achieved by a ruthenium(II) 1,10-
phenantroline centre (Figure 2.9).95,96 These assemblies exhibit broad emission 
bands with a relative short luminescence lifetime, which is less favorable for in 
vivo imaging. A significant improvement in excited state lifetimes (milliseconds 
range) and sharp emission bands can be obtained by using metals of the lanthanide 
series. Appropriate care of the chelating ligand is necessary as the f-f transitions 
are Laporte forbidden and the luminescence must be triggered by an effect called 
‘sensitization’. 
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Figure 2.9. Gd(III)-DTPA with a variety of metal assemblies are known. The green 
emitting titanium(IV) catecholate or aluminium(III) 8-hydroquinoline cores and the 
red emitting ruthenium(II) 1,10-phenantroline centre.93–95  
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5 Luminescence 
Upon absorption of light of a certain wavelength, a ligand or dye is excited to the 
singlet excited state (S1). The captured energy can be released in the form of a 
photon (ligand fluorescence) or transferred into the triplet state via an intersystem 
crossing (ISC), then released as a photon (ligand phosphorescence). This 
mechanism is characteristic for most organic dyes. As stated above, the f-f 
transitions of lanthanide ions are Laporte forbidden. Direct excitation of the 
lanthanide ions is possible but they have small absorption cross-sections. To 
obtain good luminescence a sensitization process is necessary and is depicted in 
Figure 2.10A. Generally, an organic molecule with a high molecular absorption 
coefficient is used as an energy absorber and transfers this energy towards the 
lanthanide. Energy from the ligand’s triplet state can be transferred to the excited 
state of the lanthanide where it decays to the ground state. Each transition has 
specific wavelengths, which are given for Eu(III) and Tb(III) in Figure 2.10B.97 
Generally, the energy transfers to the lanthanide ion are via the ligand triplet state, 
because the ISC is forced by the paramagnetic ion and the energy transfer via the 
singlet state is slower than ligand fluorescence or ISC.   
The triplet-mediated energy transfer of sensitized lanthanide luminescence can 
proceed via two mechanisms: the Dexter or the Förster mechanism.98,99 In the 
Dexter model the energy transfer occurs by the exchange of an electron from the 
sensitizing ligand to the lanthanide. Therefore orbital overlap is needed and small 
distances (< 10 Å) are necessary. The Förster mechanism proposes an energy 
transfer by donor-acceptor dipolar interactions. This happens ‘through space’ and 
relies on spectral overlap of the donor emission spectrum with the acceptor 
absorption spectrum. For an efficient energy transfer and subsequent 
luminescence, the energy levels between the sensitizer and the lanthanide ion 
should match.100 
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Figure 2.10. The antenna effect. (A) The antenna harvests energy through high molar 
absorption to the singlet excited state. After undergoing ISC to the triplet state, the 
antenna transfers energy to the excited state of the lanthanide. The radiative 
transition of the electrons from this excited state results in luminescent emission from 
the lanthanide ion. (B) Luminescent 4f−4f transitions of europium(III) and 
terbium(III) complexes, with their commonly observed emission wavelengths of red 
and green light, respectively.36 
The luminescence intensity of the lanthanides can easily be quenched by non-
radiative energy dissipation via vibronic modes of solvent molecules.101 This 
occurs in the inner coordination sphere or near the vicinity of the metal complex. 
The most common and very effective quencher is the O-H oscillator.102 To 
maximize the emission intensity, the lanthanide should be encapsulated by strong 
chelates, effectively shielding it from the environment.  
 
Figure 2.11. Quenching of the europium luminescence by the ν(O-H) 
overtones.103 
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6 Biocompatibility 
In the search for new contrast agents, one needs to keep in mind the 
biocompatibility of the final product. As stated before, free gadolinium(III) is 
toxic and changes to the structure of DTPA or DOTA can alter the stability of the 
whole complex. Changes to the structure can also have an effect on the 
biodistribution and residence time in the body, although long residence times are 
not always considered beneficial. Targeting groups can be added to mark specific 
cells with a bimodal CA.  
The true effect of nanoparticles in the human body has not yet been uncovered, 
but much research has been conducted towards a better understanding towards 
their biocompatibility. A prediction of biocompatibility of new NPs is frequently 
done by four parameters: particle size, particle surface properties, particle shape 
and particle structure.104–106 For a more accurate assessment about the 
biocompatible behavior, in vitro or in vivo studies should be performed. The 
particle size affects the excretion and biodistribution. Large particles (> 50 nm) 
are excreted via the spleen and liver, while smaller particles show prolonged blood 
residence times. Small particles (< 50 nm) also provide a maximum in cellular 
uptake. Another parameter is the surface properties of the NPs. A positive charge 
has a better transvascular transport into tumors, but it could be cytotoxic and could 
cause an immune response. A neutral charge of NPs results in longer circulation 
times. A profound member in this group is the FDA approved polyethylene glycol 
encapsulated IONP. The layer offers increased particle dispersibility leading to a 
better blood-circulation and decreases the excretion rate. The particle shape is 
another parameter which can influence the biocompatibility. It has been shown 
that spherical shaped NPs are excreted more rapidly than their non-spherical 
counterparts. It is not always easy to synthesize different shapes of a particle. The 
last parameter influencing biocompatibility that recently was considered is the 
particle structure. Mesoporous materials offer the possibility to act as hosts for 
guest molecules for targeted drug delivery. More research should still be done to 
increase the understanding about the parameters and their effect on the 
biocompatibility.   
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7 Scope of this work 
New MRI instruments tend to operate at higher magnetic field as this improves the 
image quality and sensitivity. Current commercially available positive contrast 
agents tend to lose their relaxivity efficiency at these higher fields, while negative 
contrast agents generally operate much better. By increasing the molecular weight, 
thus slowing the rotational correlation time, increased relaxivity efficiency 
between 20 and 100 MHz can be obtained. To further improve the performance of 
contrast agents, a bimodal approach could be used by combining two 
complementary techniques into one probe. Optical imaging has a great sensitivity, 
while MRI has superior spacial resolution. Lanthanide chelates offer great features 
such as long luminescence lifetimes and sharp emission spectra. A lot of research 
has been done on these types of compounds, however further studies into 
appropriate ligand designs and efficient lanthanide sensitization must be 
performed. BODIPY dyes are a group of organic molecules with tunable emission 
wavelengths and very bright fluorescence. The applications of these dyes are very 
broad, but the use as bimodal optical probe remains scarce and further 
optimization and its use as bimodal contrast agents should be explored. 
The goal of this PhD study is the development of new multimodal contrast agents 
for MRI and optical imaging. In a first approach potential MRI contrast agents for 
higher magnetic fields are developed. The compounds are self-assembled 
metallostar complexes with an f-block element core and three peripheral Gd-
DTPA moieties. The aromatic organic structure will act as an antenna for f-block 
luminescence and provides rigidity to effectively increase the rotational 
correlation time. The synthesis, luminescence and relaxometric properties are 
reported in chapter 3. In a second approach iron oxide nanoparticles are used as 
potential high field negative MRI CAs. Three new BODIPY dyes are synthesized 
and covalently bound onto the iron oxide NPs surface. The design, fluorescent 
data and MRI response is highlighted in chapter 4. In a final approach, different 
BODIPY analogues are coupled to Gd-DOTA to obtain positive bimodal contrast 
agents. Different azides containing BODIPYs are synthesized and coupled via 
click-chemistry. In chapter 5 the azide formation in a copper tube via a 
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diazotransfer reaction is described. Subsequent click-reaction leads to a potential 
positive contrast agent which fluorescent and relaxometric data have been 
examined. Other methods for BODIPY synthesis and azide formation are 
presented in chapter 6. 
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CHAPTER 3 
Luminescent Metallostar 
Complexes 
This chapter is based on a manuscript published in European Journal of Inorganic 
Chemistry, 2015, 4207–4216. 
“Luminescence and Relaxometric Properties of Heteropolymetallic 
Metallostar Complexes with Selectively Incorporated Lanthanide(III) Ions”, 
Matthias Ceulemans, Elke Debroye, Luce Vander Elst, Wim M. De Borggraeve, 
and Tatjana N. Parac-Vogt. 
 
 
 
This chapter builds on previous work published by Dr. Elke Debroye.1 Synthesis 
and complexation of the reported complex was done in framework of an Erasmus 
project by Miguel Roldán Albaladejo under supervision of Drs. Matthias 
Ceulemans. The synthesis leading to the triazole linked product was done by 
Pieter Vanstraelen as his internship project guided by Drs. Michael Harris and 
Drs. Matthias Ceulemans. The design and synthesis leading to the ethynyl linked 
product was done by Drs. Matthias Ceulemans. Gratitude goes towards Prof. Koen 
Binnemans for TXRF measurements. Relaxometric data were measured and fitted 
by Prof. Luce Vander Elst at the University of Mons. 
Luminescent Metallostar Complexes| 
 
48 
1  Introduction 
As mentioned in previous chapters the design of lanthanide based systems for 
potential bimodal imaging attracts a lot of attention. Complexes with both a 
paramagnetic gadolinium(III) and lanthanide(III) bearing ions can emit in a broad 
region from visible2 to NIR3 and have been intensively studied. 
Heteropolymetallic complexes with two different chelates and an integrated 
antenna remain difficult to synthesize in a controlled way due to the coordination 
similarities along the lanthanide series.  
This chapter builds on previously published work where the successful synthesis 
of a heterotetrametallic complex, (GdL1)3Eu, was reported.1 Two different 
lanthanide(III) ions were selectively incorporated into one ligand, L1. The 
resulting complex contained three Gd-DTPA moieties linked to an europium(III) 
chelate consisting of a para-substituted dipicolinic acid (DPA), and exhibited both 
high relaxivity, due to the presence of three gadolinium(III) ions and rigidity, and 
favorable europium(III) luminescence. Encouraged by these results, we further 
extend this strategy toward creating potential bimodal contrast agents with 
selectively incorporated lanthanide ions. A series of (GdL1)3Ln complexes in 
which Ln represents different luminescent lanthanide(III) ions, has been prepared. 
In addition, two novel ligands which contain an ethynyl or a triazole linker 
between the two aromatic centers, have been synthesized with the aim to decrease 
the excited triplet state of the ligand in order to provide better energy transfer to 
ytterbium(III).3 Using the same selective synthetic approach, a series of 
heterotetrametallic complexes based on these novel ligands have been synthesized 
and characterized. The magnetic and luminescent properties of the complexes 
have been studied and their potential as bimodal contrast agents for MRI and 
optical imaging has been evaluated. 
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2 Results and discussion 
2.1 Ligand design and synthesis  
The general ligand design is based on attaching a DTPA scaffold via an amide 
linkage to para-substituted dipicolinic acid (DPA), which has previously been 
demonstrated to form tris complexes with lanthanide(III) ions.1 This approach 
allows for incorporation of different antennas between coordinating moieties to 
sensitize the luminescent lanthanide ion. A first method has been previously 
reported by our group and resulted in the synthesis of a Eu(III) metallostar 
complex.1 It uses a Suzuki-Miyaura coupling4 to obtain a fully protected 
dipicolinate derivative, in which gadolinium(III) could be selectively incorporated 
in the DTPA unit. Subsequent removal of the protecting groups and coordination 
to a luminescent lanthanide(III) ion (Ln = Eu,1 Tb, Dy, Sm, Ho, Tm, and Yb) 
yields the desired metallostar complex (Scheme 3.1). All metallostar complexes 
contain three gadolinium(III)-DTPA units, but differ in the nature of the central 
lanthanide(III) ion bound to the dipicolinate units. 
 
Scheme 3.1. Schematic representation of the complex GdL1 and the 
heterotetrametallic metallostar (GdL1)3Ln (Ln = Eu(III),1 Dy(III), Tb(III), Ho(III), 
Nd(III), Sm(III), Tm(III), and Yb(III)). 
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The synthesis of the novel ligand L2 makes use of Sonogashira cross-couplings 
reaction and employs a slightly altered synthetic pathway than the one previously 
reported by Bünzli et al.5 The first step is the protection of 4-iodobenzylamine 
with t-boc-anhydride resulting in compound (1). Compound (1) is subsequently 
coupled to trimethylsilylacetylene via a Sonogashira cross-coupling (2) and 
subsequent deprotection of the trimethylsilylgroup yields compound (3). The 
NMR spectrum clearly shows the disappearance of the highly shielded 
trimethylsilyl protons at 0.24 ppm and the appearance of a single proton peak of 
the ethynyl group at 3.06 ppm. Compound (3) is able to undergo another 
Sonogashira cross-coupling under the same conditions to dimethyl-4-bromo-2,6-
pyridinedicarboxylate, resulting in compound (4) (Scheme 3.2). 
 
Scheme 3.2. Synthetic pathway GdL2: a) Boc-anhydride, b) ethynyl trimethylsilane, 
CuI, PdCl2(PPh3)2, c) 1 M TBAF, d) dimethyl-4-bromo-2,6-pyridinedicarboxylate, 
CuI, PdCl2(PPh3)2. 
The t-Boc group is selectively deprotected using trifluoroacetic acid in 
dichloromethane (50/50), which is confirmed by the disappearance of the tert-
butyl peaks at 1.45 ppm and the persistence of the methyl peaks at 4.06 ppm in the 
NMR spectrum. This approach results in a free amine (5) which can be coupled to 
the one free acid of the DTPA t-butylester via amide synthesis, resulting in a fully 
protected ligand (6). At last, the DTPA tert-butyl esters are selectively cleaved 
using a 6 M HCl solution, resulting in compound (7). (Scheme 3.3) The acidic 
groups of DTPA can then be further coordinated to gadolinium(III). The 
complexation was performed by using GdCl3•6H2O in pyridine and the absence of 
free lanthanide ions is verified by the addition of an arsenazo indicator solution.6 
Selective removal of the methyl ester protective groups from the dipicolinate 
moiety is done under alkaline conditions and the final ligand is mixed with a 
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luminescent lanthanide (LnCl3•xH2O) salt (Ln = Eu, Tb, Dy, Sm, Ho, Tm, Yb). By 
this approach the desired metallostar tris complexes (GdL2)3Ln are generated, as 
schematically shown in Scheme 3.4.  
 
Scheme 3.3. Synthetic pathway GdL2: a) DTPA t-butylester, TBTU, DIPEA, 
b) 6 M HCl, c) GdCl3·6H2O, pyridine, d) K2CO3.  
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Scheme 3.4. Schematic representation of the complex GdL2 and the 
heterotetrametallic metallostar (GdL2)3Ln (Ln = Eu(III), Dy(III), Tb(III), 
Nd(III), Sm(III), Tm(III), and Yb(III)). 
The synthesis of ligand L3 employs click chemistry to combine compound (3) with 
dimethyl-4-azido-pyridine-2,6-dicarboxylate (8) to form the protected compound 
(9). Coupling of this compound to a tert-butyl protected DTPA unit with TBTU 
and a base, subsequent deprotection with a 50:50 TFA/DCM mixture yields a 
ligand with a DTPA containing moiety. Complexation of this DTPA unit with 
Gd(III) in pyridine yields the methoxy protected GdL3 ligand. A saponification 
step with K2CO3 provides us with GdL3. No loss of gadolinium(III) was observed 
during this reaction. A subsequent complexation step, leads to a novel red 
luminescent (GdL3)3Eu metallostar complex depicted in Scheme 3.6. 
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Scheme 3.5. Synthetic pathway of GdL3: a) NaN3, b) compound (3), CuSO4, 
sodium ascorbate, c) TFA/DCM, d) DTPA t-butylester, TBTU, DIPEA, e) 
DCM/TFA, f) GdCl3·6H2O, pyridine, d) K2CO3.  
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Scheme 3.6. Schematic representation of the complex GdL3 and the 
metallostar (GdL3)3Eu. 
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2.2 Photophysical properties  
The absorption spectrum of the GdL1 complex has a well defined maximum 
around 282 nm (ε = 4250 cm-1M-1) caused by the π→π* transition of DPA.7 The 
excitation spectrum shows a broad band between 250 and 300 nm with a 
maximum at 295 nm. The absorption spectra of GdL2 and the tris complex 
(GdL2)3Ln, both show an absorption maximum at 315 nm. The molar extinction 
coefficient of the free complex GdL2 at this maximum is ε315 = 6692 cm-1M-1, 
while the one tris-complex has ε315 = 11000 cm-1M-1.  
 
Figure 3.1. Normalized absorption spectra of GdLX (X = 1-3) at room 
temperature. 
In the emission spectra of (GdL1)3Eu, (GdL2)3Eu and (GdL3)3Eu metallostar 
complexes, the 5D0→7F1 transition shows splitting into three bands, which 
suggests a slightly deformed D3 symmetry around the central ion (Figure 3.2).1,8 
This is further supported by the ratio of the 5D0→7F2 and 5D0→7F1 transition 
which is ca. 5-6. 
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Figure 3.2. Corrected and normalized emission spectra at room 
temperature of (GdL1)3Eu (λexc = 293 nm), (GdL2)3Eu (λexc = 315 nm), 
and (GdL3)3Eu (λexc = 262 nm). 
Luminescence decays of the metallostar complexes (GdL1)3Eu and (GdL2)3Eu 
have been measured in water and D2O, and the results are shown in Table 3.2. The 
decrease of the luminescence lifetime in water compared to D2O is due to the 
presence of inner sphere high-energy O-H vibrations and can be used for 
determining the number of coordinated water molecules. The best fit was observed 
by applying a bi-exponential decay, which suggests the presence of two different 
species in solution. The phenomenological equation9,10 has been employed to 
determine the hydration number q with an accuracy of ± 0.3.  
𝑞Eu (H2O) = 1.11(Δkobs − 0.31 + 0.44qOH + 0.99qNH + 0.075qCONH) (eq. 3.1) 
 
In eq. 3.1, Δkobs represents the difference of the decay rate constants 
𝑘𝐻2𝑂(1 𝜏𝐻2𝑂)⁄  and 𝑘𝐷2𝑂(1 𝜏𝐷2𝑂)⁄ , expressed in ms-1 for Eu(III). The qX stands for 
the number of OH, NH or CONH groups directly bound to the lanthanide center. 
The results indicate that at the low concentrations used for luminescence 
measurements (2.0·10-5 M), an equilibrium has been set between the bis and tris 
complex. These findings are consistent with those previously reported for 
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(DPA)3Eu complexes, in which a significant amount of bis complexes was 
detected in micromolar concentrations range.11 As no water is present in the first 
coordination sphere of the central ion in the tris complex, while in the bis complex 
there should be three water molecules bound. This allows for determining the ratio 
of tris/bis complex. An increase of the ratio of tris to bis complex, from 80:20 for 
(GdL1)3Eu to 93:7 for (GdL2)3Eu, is seen upon introduction of an ethynyl linker in 
the ligand structure. The luminescent quantum yields 𝑄𝐿𝐿𝑛 were determined upon 
ligand excitation by a comparative method, using a solution of Rhodamine 101 in 
ethanol (Q = 100%) as the standard. The quantum yield was determined according 
to the following equation: 
𝑄𝐿
𝐿𝑛 = 𝑄𝑆 ∙ 𝐼𝑋𝐼𝑆 ∙ 𝐴𝑆(𝜆𝑒𝑥𝑐)𝐴𝑋(𝜆𝑒𝑥𝑐) ∙ 𝜂𝑋2𝜂𝑆2 (eq. 3.2) 
 
In this equation, the s and x refer to the standard and the unknown sample 
respectively, I represents the corrected total integrated emission intensity, A is the 
absorbance at the excitation wavelength and η the refractive index of the solution 
(ηwater = 1.34 and ηethanol = 1.36). The quantum yields are summarized in Table 3.3. 
Apparently due to the lower ππ* energy level of GdL2, the quantum yield of the 
complex drops from 9.8% for (GdL1)3Eu to 1.5% of (GdL2)3Eu, indicating that L2 
is less efficient in sensitizing europium emission. The observed quantum yield for 
(GdL3)3Eu was only 0.5%. Direct excitation into the lanthanides is possible but is 
very inefficient because the f-f transitions are Laporte forbidden. The intrinsic 
quantum yields 𝑄𝐿𝑛𝐿𝑛 (Ln(III) = Eu(III), Tb(III)) can however be estimated 
according to the following equations comprising the ratio between the observed 
(τobs) and radiative (τrad) lifetimes. 
1 τobs =  𝐴𝑀𝐷,0 ∙ 𝑛3 ∙ �𝐼𝑡𝑜𝑡𝐼𝑀𝐷� (eq. 3.3) 
𝑄𝐿𝑛
𝐿𝑛 =  τ𝑜𝑏𝑠
τ𝑟𝑎𝑑
 (eq. 3.4) 
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The Einstein coefficient AMD,0 equals 14.65 s-1, n is the refractive index set to n𝐻2𝑂 = 1.34, which is equal to that of the neat solvent, and (Itot/IMD) represents the 
ratio of the total integrated intensity of the transitions to the transition of the 
magnetic dipole (MD). The intrinsic quantum yield values 𝑄𝐸𝑢𝐸𝑢 for both the GdL
1 
and GdL2 complexes are in the range of 22-24%. At last, we can acquire the ratio 
between the quantum yield under ligand excitation and the intrinsic quantum yield 
to obtain the sensitization efficiency (ηsens) of the ligand: 
𝜂𝑠𝑒𝑛𝑠 =  𝑄𝐿𝐸𝑢𝑄𝐸𝑢𝐸𝑢 (eq. 3.5) 
This results in a sensitization efficiency for (GdL1)3Eu of 47% and only 6.3% for 
(GdL2)3Eu. These values are lower than those for the parent (DPA)3Eu complex, 
which has QEu = 24% and ηsens = 61%.7 
Dysprosium(III) complexes with GdL1 and GdL2, showed yellow emission due to 
transitions 4F9/2→6HJ (J = 15/2, 13/2 and 11/2). (GdL1)3Dy clearly shows these 
three transitions of Dy(III) with some ligand emission, while the (GdL2)3Dy 
emission spectrum is dominated by ligand emission due to poor sensitization 
(Figure 3.3). The 4F9/2→6H15/2 transition, which is typically observed at 485 nm, 
has completely disappeared under the ligand emission tail. However, the 
4F9/2→6H13/2 transition which is located around 575 nm is clearly visible together 
with the weak transition of 4F9/2→6H11/2 at 665 nm. Quantum yields for the 
dysprosium(III) samples have been measured by the method using a solution of 
Rhodamine 101 in ethanol (Q = 100%) as a standard. Using eq. 3.2, low values of 
1.2% for (GdL1)3Dy and 0.8% for (GdL2)3Dy are obtained (Table 3.3). The poor 
efficiency of the ligands to sensitize dysprosium(III) could already be observed in 
the luminescence spectra. The amount of water molecules can be calculated using 
the phenomenological equation 3.6:12–14 
𝑞Dy (H2O) = 21.1 ∙ Δkobs − 0.60  (eq. 3.6) 
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Values of 1.2 and 0.3 are obtained for (GdL1)3Dy and (GdL2)3Dy respectively, 
which results in a ratio of tris to bis complex of 60:40 and 90:10. 
 
Figure 3.3. Corrected and normalized emission spectra at room temperature 
of (GdL1)3Dy (λexc = 293 nm) and (GdL2)3Dy (λexc = 315 nm). 
Characteristic green emission is observed for terbium(III) complexes of both GdL1 
and GdL2, exciting the ligand at 295 nm and 315 nm respectively, due to the 
Tb(III) 5D4→7FJ (J = 6-0) transitions (Figure 3.4). Quantum yields for terbium(III) 
complexes are relative high, using the comparative method of Rhodamine 101, 
ranging from 30% for (GdL1)3Tb to 15% for (GdL2)3Tb. The amount of water 
molecules bound to the luminescent centre can also be determined out of lifetime 
measurements in H2O and D2O using eq. 3.7 and are shown Table 3.3. 9,15 
𝑞Tb (H2O) = 5 ∙ (Δkobs − 0.06)  (eq. 3.7) 
The overall ratios of tris to bis complexes for (GdL1)3Tb and (GdL2)3Tb are 57:43 
and 73:27 respectively. These ratios are lower than for the other lanthanides, but 
still very high quantum yields can be obtained, since the energy from the excited 
state of terbium(III) is poorly quenched by water.  
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Figure 3.4. Corrected and normalized emission spectra at room temperature 
of (GdL1)3Tb (λexc = 293 nm) and (GdL2)3Tb (λexc = 315 nm). 
Tris complexes of all other luminescent lanthanides such as neodymium(III), 
holmium(III), samarium(III) or thulium(III) unfortunately only give rise to ligand 
emission and no distinct peaks for lanthanide emission could be observed. The 
low energy of the ππ* state apparently makes both L1 and L2 poor sensitizers for 
these lanthanides.  
Table 3.1. TXRF ratios of Gd to Ln of the metallostar complexes. 
ratio Tb Dy Ho Sm Nd Tm Yb 
(GdL1)-Ln 2.49 2.80 3.07 3.54 3.18 3.73 1.92 
(GdL2)-Ln 3.06 3.06 2.92 2.59 2,70 / 3.03 
 
However, in the case of the ytterbium(III) ion complex (GdL2)3Yb emission at 980 
nm corresponding to 2F5/2 → 2F7/2 transition could be observed when the complex 
was measured in the solid state, while it was absent for (GdL1)3Yb. Luminescence 
in the IR region was not seen in aqueous solutions of either (GdL1)3Yb nor 
(GdL2)3Yb, most likely because of the quenching of the radiative emission by 
water. (Figure 3.5) 
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Figure 3.5. Corrected and normalized solid state emission spectrum of 
(GdL2)3Yb (λexc = 315 nm). 
Table 3.2. Luminescence lifetimes of the different (GdL)3Ln 
complexes (Ln = Eu, Dy, Tb), average number of calculated 
water molecules in the first coordination sphere (q) and the ratio 
of tris/bis complex under the conditions of the measurements 
(2.0·10-5 M). 
 H2O D2O q 
Ratio 
tris/bis 
(GdL1)3Eua 0.23 ms 1.12 ms 0.6 80:20 
(GdL1)3Dy 9 µs 39 µs 1.2 60:40 
(GdL1)3Tb 1.42 ms 2.42 ms 1.3 57:43 
(GdL2)3Eu 0.20 ms 1.11 ms 0.2 93:7 
(GdL2)3Dy 9 µs 14 µs 0.3 90:10 
(GdL2)3Tb 2.20 ms 2.40 ms 0.8 73:27 
[a] From ref. 1    
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Table 3.3. Calculated quantum yields of the (GdL1)3Ln  
(λexc = 293 nm) and (GdL2)3Ln complexes (λexc = 315 nm). 
Ln (GdL1)3Ln (GdL2)3Ln 
Eu 9.8% 1.5% 
Dy 1.2% 0.8% 
Tb 30.9% 15.3% 
2.3 Relaxometric studies  
The efficiency of a 1 mM solution of gadolinium(III) agent to shorten the 
longitudinal relaxation time (T1) can be derived from proton NMRD profiles by 
measuring the water proton relaxivity (r1) as a function of the magnetic field 
strength. The relaxation rate is enhanced by the dipolar interaction between the 
water molecules and the paramagnetic centre, gadolinium(III). Besides inner 
sphere contributions,[11,42] which result from the water molecules directly bound to 
the paramagnetic centre and exchanging with the bulk, outer sphere[43] interactions 
of water have to be taken into account and in some cases second sphere 
interactions[44] can have significant effects. Several parameters are defined for the 
inner sphere water molecules. While water molecules directly bound to the 
luminescent centre have a negative effect on the luminescence, a high relaxivity 
can be obtained with a higher amount of water molecules directly bound to the 
paramagnetic centre (q). Other parameters are the distance between 
gadolinium(III) and water (r), the water residence time (τM), the rotational 
correlation time of the paramagnetic centre (τR), the electronic relaxation time of 
gadolinium(III) at zero field (τS0) and the correlation time modulating the 
electronic relaxation (τv).  
The 1H NMRD profiles of GdL1 and (GdL1)3Eu have been reported in a recent 
publication.1 The profile of (GdL1)3Eu displayed a characteristic hump between 20 
and 100 MHz which is assigned to the formation of a supramolecular structure. At 
20 MHz and 310 K, the relaxivity is enhanced to 8.3 s-1mM-1 for GdL1 and to 9.6 
s-1mM-1 for (GdL1)3Eu with respect to 3.8 s-1mM-1 found for Gd-DTPA, as could 
be expected given the higher molecular weight of the synthesized chelates. Taken 
into account the presence of three gadolinium ions per metallostar compound, a 
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longitudinal relaxation rate of 28.8 s-1mM-1 per (GdL1)3Eu molecule is obtained at 
20 MHz and 310 K. 
In this chapter the relaxometric properties of metallostars based on the L2 ligand 
have been examined. Similarly to (GdL1)3Eu, the proton NMRD profiles of 
(GdL2)3Ln metallostars (measured in water at pH 7.4 and 310 K) show a hump 
between 20 and 100 MHz, characteristic of supramolecular structures in solution 
(Figure 3.6). It is to be pointed out that the NMRD profile of GdL2 is quite similar 
to those of the metallostar complexes suggesting a self aggregation of the 
monomer to form dimeric, trimeric or multimeric species. 
Table 3.4. Parameters obtained by fitting the 1H NMRD data in water at pH 7.4 and 
310 K. Fixed values q = 1, r = 0.31 nm, d = 0.36 nm, τM = 1500 ns and  
D = 3.0·10-9 m2s-1. 
Parameter 
(ps) 
Gd-DTPA 
[a] GdL
2 (GdL2)3Eu (GdL2)3Dy (GdL2)3Tb 
τR 54 ± 1 809 ± 48 1000 ± 3 818 ± 35 916 ± 41 
τS0 87 ± 3 83 ± 1 64 ± 1 70 ± 1 66 ± 1 
τV 25 ± 3 20 ± 1 21 ± 1 18 ± 1 17 ± 1 
[a] From ref. 20 
The NMRD data shown in Figure 3.6 are fitted to the Solomon-Bloembergen-
Morgan equation, which as expected indicate a significant increase of τR compared 
to Gd-DTPA. However, due to the possible equilibria between tris and bis 
complexes, the precise values of τR are difficult to determine. It should be noted 
that equilibria between tris and bis complex observed in the luminescence 
measurements might be absent, or present to lesser extent due to the higher 
concentrations used in the NMRD measurements. Also, from the stability 
constants of Ln-DTPA and Ln(DPA)3 complexes it is plausible that redistribution 
of Gd(III) and Eu(III) ions between both the ligands may take place. However, 
this is unlikely as the emission spectrum of (GdL1)3Eu and (GdL2)3Eu does not 
show the splitting of 5D0→7F1 transition, which would be expected to occur if 
Eu(III) would be complexed in the DTPA part. The relaxivities measured at 20 
MHz at temperatures ranging between 25 and 45 °C increased by less than 13% 
indicating a slow water exchange. During the fitting procedure, τM was fixed to 
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1500 ns for all metallostars as well as for the GdL2 complex. At 20 MHz and 310 
K, the relaxivity of the complexes (GdL2)3Ln with Ln = Eu(III), Dy(III) and 
Tb(III), have been determined to be very similar (8.09, 7.60 and 7.24 s-1mM-1 
respectively). Assuming the presence of three Gd-DTPA moieties, the expected r1 
relaxivity of the molecules would be 24.27, 22.8 and 21.72 s-1mM-1 per 
metallostar complex, which is slightly lower than the value of 28.8 s-1mM-1 
observed for the (GdL1)3Eu metallostar.1  
 
Figure 3.6. NMRD profiles of GdL2 and (GdL2)3Ln (with Ln = Eu, Dy, 
and Tb) compared to Gd-DTPA in water at 310 K. 
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3 Conclusions 
In this chapter, the selective incorporation of several lanthanides into two ditopic 
ligands has been accomplished leading to metallostar complexes which exhibited 
favorable luminescent and relaxometric properties for potential use as bimodal 
MRI/OI agents. Incorporation of Eu(III), Dy(III) and Tb(III) into the complexes 
results in emission in the visible region upon excitation into the ligand levels. 
Quantum yields of up to 10% for (GdL1)3Eu were achieved, with a sensitization 
efficiency (ηsens) of 47%. Introducing a ligand having an ethynyl group (GdL2) or 
triazole ring (GdL3), lowers the energy of the ππ* excited state, resulting in the 
decrease of the quantum yield of the metallostar complex to 1.5% and 0.5% 
respectively, and a decrease of the sensitization efficiency to only 6.3% for 
(GdL2)3Eu. The same effect has been observed for dysprosium(III) and 
terbium(III) complexes. At the concentrations used in the luminescence 
measurements, the tris complexes partially convert into bis complexes, however, 
the presence of an extra linker between the aromatic rings in GdL2 allows for a 
larger tris to bis complex ratio, as compared to the GdL1 ligand. The lower energy 
resulting from this linker also lowers the ππ* excited state of GdL2 allowing it to 
sensitize ytterbium(III) in the solid state. The NMRD profiles of (GdL2)3Ln 
complexes display a characteristic hump between 20 and 100 MHz due to the 
formation of a supramolecular structure, with enhanced longitudinal relaxivity of 
up to 25 s-1mM-1 per metallostar assembly at 20 MHz and 310 K. 
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4 Experimental section 
General Synthesis of (GdL1)3Ln. All complexes were synthesized by applying 
the previously reported procedure3 and by replacing EuCl3 with appropriate 
LnCl3·xH2O salt. The complexes have been characterized by TXRF spectrometry, 
IR and optical spectroscopy.  
Synthesis of tert-butyl 4-iodobenzylcarbamate (1) 
 
4-Iodobenzylamine (1 eq.; 0.680 g; 2.92 mmol) and triethylamine (1.5 eq.; 4.38 
mmol; 0.443 g) is dissolved in 20 ml THF. The solution was cooled in an ice bath 
and t-boc-anhydride (1.5 eq.; 4.38 mmol; 0.955 g) is slowly added. It was allowed 
to stir overnight at room temperature and the solvent was evaporated. 20 ml of 
water was added and the product was extracted with EtOAc (3 x 20 ml). The 
combined organic layer was washed with brine and dried over MgSO4. The 
solvent was evaporated and yielded a white solid (yield: 0.966 g; 99%). ESI-MS 
(MeOH, m/z): calcd: 356.17 g/mol [M+H]+, found: 356.6 g/mol [M+Na]+. 1H 
NMR (300 MHz, CDCl3, δ ppm): 1.45 (s, 9H, t-Bu), 4.23 (d, 3JH,H = 5.6 Hz, 2H, 
NHCH2C), 4.87 (broad, 1H, NHCH2C), 7.01 (d, 3JH,H = 8.4 Hz, 2H, I-CCHCHC), 
7.65 (d, 3JH,H = 8.4 Hz, 2H, I-CCHCHC). 13C NMR (75 MHz, CDCl3, δ ppm): 
28.38; 44.10; 79.71; 92.59; 129.36; 137.62; 138.73; 155.83. 
Synthesis of tert-butyl 4-((trimethylsilyl)ethynyl)benzylcarbamate (2)  
 
Product (1) (1 eq.; 0.966 g; 2.90 mmol), copper(II) iodide (10 mol%; 0.055 g; 
0.290 mmol), bis(triphenylphosphine)palladium(II)chloride (5 mol%; 0.101 mg; 
0.145 mmol), triethylamine (2 eq.; 0.587 g; 5.80 mmol) were suspended in 10 ml 
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of dry THF and stirred for 15 minutes under inert atmosphere. 
(Trimethylsilyl)acetylene (1.2 eq.; 0.118 g; 1.2 mmol) was added and stirred 
overnight. The solution was diluted with diethylether (50 ml) and the mixture was 
filtrated over celite. The crude product was purified using silica (eluent = 
chloroform) and yielded the desired product as an off white solid (yield: 0.704 g; 
80%). ESI-MS (MeOH, m/z): calcd: 326.46 g/mol [M+Na]+, found: 326.5 g/mol 
[M+Na]+. 1H NMR (300 MHz, CDCl3, δ ppm): 0.24 (s, 9H, Si-CH3), 1.45 (s, 9H, 
t-Bu), 4.29 (d, 3JH,H = 5.6 Hz, 2H, NHCH2C), 4.85 (broad, 1H , NHCH2C), 7.20 
(d, 3JH,H = 7.6 Hz, 2H, CCHCHC), 7.42 (d, 3JH,H = 7.6 Hz, 2H, CCHCHC). 13C 
NMR (75 MHz, CDCl3, δ ppm): 0.37; 28.34; 44.46; 79.68; 94.18; 104.86; 122.11; 
127.23; 132.20; 139.43; 155.88. 
Synthesis of tert-butyl 4-ethynylbenzylcarbamate (3)  
 
Product (2) (1 eq.; 0.671 g; 2.21 mmol) was dissolved into 20 ml THF and cooled 
to 0 °C. TBAF (1 M) (2 eq.; 4.42 mmol; 4.02 mL) was added and stirred at 0 °C 
for 1 hour. After the reaction, 50 ml of a water/DCM mixture was added. The 
organic layer was collected, dried and evaporated. The crude product was purified 
using silica (eluent = DCM) resulting in a white solid (yield: 0.382 g; 75%). ESI-
MS (MeOH, m/z): calcd: 354.28 g/mol [M+Na]+, found: 354.6 g/mol [M+Na]+. 1H 
NMR (300 MHz, CDCl3, δ ppm): 1.45 (s, 9H, t-Bu), 3.1 (s, 1H, CCH), 4.30 (d, 
3JH,H = 5.9 Hz, 2H, NHCH2C), 4.90 (broad, 1H, NHCH2C), 7.23 (d, 3JH,H = 8.3 
Hz, 2H, CCHCHC), 7.44 (d, 3JH,H = 8.3 Hz, 2H, CCHCHC). 13C NMR (75 MHz, 
CDCl3, δ ppm): 28.38; 44.37; 79.70; 83.43; 121.02; 127.1; 127.29; 132.34; 
139.84; 155.87. 
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Synthesis of dimethyl 4-((4-(((tert-
butoxycarbonyl)amino)methyl)phenyl)ethynyl)pyridine-2,6-dicarboxylate (4)  
 
4-Bromopyridine-2,6-dimethylcarboxylate (1 eq.; 0.411 g; 1.50 mmol), CuI (10 
mol%, 28.6 mg; 0.15 mmol) and bis(triphenylphosphine)palladium(II) (5 mol%, 
52.7 mg; 0.075 mmol) were added to 10 ml dry THF. Triethylamine (2 eq.; 0.304 
g; 3.00 mmol) was added and the mixture was allowed to stir for 15 minutes. 
Product (3) (1.1 eq.; 0.382 g; 1.65 mmol) was added and the mixture was stirred 
for 4 hours at 40 °C. The THF was evaporated, CH2Cl2 was added and the 
suspension was washed with water. The crude product was dissolved in methanol 
and stirred for 30 minutes. The precipitate was filtered off and dried to obtain the 
desired product as a light brown solid (yield: 0.535 g; 84%). ESI-MS (MeOH, 
m/z): calcd: 447.44 g/mol [M+Na]+, found: 447.7 g/mol [M+Na]+. 1H NMR (300 
MHz, CDCl3, δ ppm): 1.47 (s, 9H, t-Bu), 4.04 (s, 6H, OMe), 4.36 (d, 3JH,H = 6.1 
Hz, 2H, NHCH2C), 4.92 (broad, 1H, NHCH2C), 7.31 (d, 3JH,H = 8.1 Hz, 2H, 
CCHCHC), 7.50 (d, 3JH,H = 8.1 Hz, 2H, CCHCHC); 8.36 (s, 2H, CHCC≡C). 13C 
NMR (75 MHz, CDCl3, δ ppm): 28.39; 44.36; 53.33; 79.83; 85.41; 96.79; 120.24; 
127.54; 129.65; 132.36; 132.73; 141.15; 148.44; 155.88; 164.75. 
Synthesis of dimethyl 4-((4-(aminomethyl)phenyl)ethynyl)pyridine-2,6-
dicarboxylate (5)  
 
Product (4) (1 eq.; 0.212 g; 0.5 mmol) was dissolved in 10 ml of a DCM/TFA 
(50/50) mixture and stirred for 12 h at room temperature. The solvents were 
evaporated and 10 ml DCM/MeOH (6/4) was added and evaporated. The crude 
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product was dissolved in DCM and washed with a saturated aqueous NaHCO3 
solution and with brine, then dried over MgSO4 (yield: 0.151 g; 93%). ESI-MS 
(MeOH, m/z): calcd: 347.32 g/mol [M+Na]+, found: 347.7 g/mol [M+Na]+. 1H 
NMR (300 MHz, D5-pyr, δ ppm): 3.91 (s, 6H, OMe), 4.68 (s, 2H, NHCH2C), 4.92 
(broad, 1H, NHCH2C), 7.72 (d, 3JH,H = 7.9 Hz, 2H, CCHCHC), 7.83 (d, 3JH,H = 
7.9 Hz, 2H, CCHCHC); 8.37 (s, 2H, CHCC≡C). 13C NMR (75 MHz, CDCl3, δ 
ppm): 53.33; 85.24; 97.02; 119.75; 127.38; 129.63; 132.01; 132.14; 132.32; 
134.59; 148.40; 164.75. 
Synthesis of dimethyl 4-((4-(5-(2-(bis(2-(tert-butoxy)-2-oxoethyl)amino)ethyl)-
8-(2-(tert-butoxy)-2-oxoethyl)-12,12-dimethyl-3,10-dioxo-11-oxa-2,5,8-
triazatridecyl)phenyl)ethynyl)pyridine-2,6-dicarboxylate (6)  
 
Product (5) (1.1 eq.; 0.28 mmol; 0.90 g) was dissolved in 10 mL dry DMF and 
N,N-diisopropylethylamine (1.5 eq.; 0.38 mmol; 66 µL) was added to the solution. 
The mixture was stirred for 15 minutes at room temperature under inert 
atmosphere. At the same time, the DTPA tert-butyl ester (1 eq.; 0.25 mmol; 0.156 
g), TBTU (1.5 eq.; 0.38 mmol; 0.121 g) and N,N-diisopropylethylamine (1 eq.; 
0.25 mmol; 44 µL) were dissolved in 10 mL dry DMF in a three neck flask and 
stirred for 15 minutes at room temperature under argon atmosphere. The solution 
from flask 1 was added dropwise over a period of 10 minutes to the three-neck 
flask 2 and the mixture was stirred at room temperature under argon atmosphere 
for 24 hours. After evaporation, the residue was redissolved in DCM. The 
suspension was washed with a saturated aqueous NaHCO3 solution and with brine. 
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The organic phase was dried with magnesium sulfate and evaporated under 
reduced pressure. The obtained product was further purified with silica column 
chromatography (eluent: CHCl3/ 5% MeOH/ 0.66% NH3) and the collected 
fractions were evaporated and dried under vacuum at 50 °C, yielding a yellow oil 
(yield: 0.181 g; 70%). ESI-MS (MeOH, m/z): calcd: 947.08 g/mol [M+Na]+, 
found: 947.4 g/mol [M+Na]+. 1H NMR (300 MHz, CDCl3, δ ppm): 1.44 (s, 36H, t-
Bu); 2.64 (t, 4H, NCH2CH2N), 2.78 (t, 4H, NCH2CH2N), 3.24 (s, 2H, 
NCH2C(O)NH), 3.33 (s, 8H, NCH2C(O)O), 4.04 (s, 6H, OMe), 4.51 (d, 3JH,H = 
6.2 Hz, 2H, NHCH2C), 7.38 (d, 3JH,H = 8.2 Hz, 2H, CCHCHC), 7.53 (d, 3JH,H = 
8.2 Hz, 2H, CCHCHC); 8.35 (s, 2H, CHCC≡C), 8.88 (broad, 1H, NHCH2C). 13C 
NMR (75 MHz, CDCl3, δ ppm): 28.16; 28.42; 38.61; 42.67; 52.10; 53.32; 53.76; 
55.69; 81.09; 85.10; 97.31; 119.65; 128.13; 129.59; 132.13; 134.67; 142.06; 
148.43; 164.77; 170.51. 
Synthesis of 2,2',2'',2'''-((((2-((4-((2,6-bis(methoxycarbonyl)pyridin-4-
yl)ethynyl)benzyl)amino)-2-oxoethyl)azanediyl)bis(ethane-2,1-
diyl))bis(azanetriyl))tetraacetic acid (7)  
 
The protected ligand precursor (6) (1 eq.; 0.19 mmol; 0.175 g) was dissolved in a 
6 M HCl solution and stirred for 1 hour at room temperature under argon 
atmosphere. The solvent was evaporated, water was added and the solution was 
evaporated again (2x). The product was redissolved in water and the pH was 
adjusted from circa 2 to 7 with pyridine. The solvents were evaporated and dried 
under vacuum at 50 °C as a pale yellow oil (yield: 0.176 mmol; 93%). 1H NMR 
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(300 MHz, D5-pyr, δ ppm): 2.64 (t, 4H, NCH2CH2N), 2.78 (t, 4H, NCH2CH2N), 
3.24 (s, 2H, NCH2C(O)NH), 3.91 (s, 6H, OMe), 4.15 (s, 8H, NCH2C(O)O), 4.80 
(d, 3JH,H = 6.4 Hz, 2H, NHCH2C), 7.57 (d, 3JH,H = 8.3 Hz, 2H, CCHCHC), 7.62 (d, 
3JH,H = 8.3 Hz, 2H, CCHCHC); 8.35 (s, 2H, CHCC≡C). 
Synthesis of dimethyl 4-azidopyridine-2,6-dicarboxylate (8) 
 
Dimethyl 4-bromopyridine-2,6-dicarboxylate (1 eq.; 1.5 mmol; 0.400 g) was 
dissolved in 5 mL DMF and NaN3 (5 eq.; 7.3 mmol; 0.475 g) was added and 
stirred at 60 °C overnight. After the reaction the solution was added into 75 mL of 
water under stirring. A white precipitate was formed and collected via filtration 
(yield: 0.244 g; 71%). EI-MS (MeOH, m/z): calcd: 237.18 g/mol [M+H]+, found: 
237 g/mol [M+H]+. 1H NMR (300 MHz, CDCl3, δ ppm): 4.03 (s, 6H, OMe), 7.94 
(2H, CH); 13C NMR (75 MHz, CDCl3, δ ppm): 53.5; 118.1; 149.9, 151.8, 164.5. 
Synthesis of dimethyl 4-(4-(4-(((tert-butoxycarbonyl)amino)methyl)phenyl)-
1H-1,2,3-triazol-1-yl)pyridine-2,6-dicarboxylate (9) 
 
Compound (8) (1 eq.; 0.73 mmol; 0.172 g) and compound (3) (1 eq.; 0.73 mmol; 
0.168 g) were dissolved in dioxane. Copper(II)sulfate (10 mol%) and sodium 
ascorbate (20 mol%) are dissolved in a small quantity of water and added to the 
mixture and the solution was kept at 30 °C for 24 h. After evaporation of the 
solvent, an orange oily liquid is obtained and crystallized from methanol (yield: 
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0.255 g; 75%). ESI-MS (MeOH, m/z): calcd: 468.47 g/mol [M+H]+, found: 490.6 
g/mol [M+Na]+. 
Synthesis of dimethyl 4-(4-(4-(aminomethyl)phenyl)-1H-1,2,3-triazol-1-
yl)pyridine-2,6-dicarboxylate (10) 
 
Compound (8) (1 eq.; 0.55 mmol; 0.255 g) was dissolved in 10 ml of a DCM/TFA 
(50/50) mixture and stirred for 12 h at room temperature. The solvents were 
evaporated and 10 ml DCM/MeOH (6/4) was added and evaporated. The crude 
product was dissolved in DCM and washed with a saturated aqueous NaHCO3 
solution and with brine, then dried over MgSO4 (yield: 0.158 g; 78%). ESI-MS 
(MeOH, m/z): calcd: 390.47 g/mol [M+Na]+, found: 757 g/mol [2M+Na]+. 
Synthesis of dimethyl 4-(4-(4-(5-(2-(bis(2-(tert-butoxy)-2-
oxoethyl)amino)ethyl)-8-(2-(tert-butoxy)-2-oxoethyl)-12,12-dimethyl-3,10-
dioxo-11-oxa-2,5,8-triazatridecyl)phenyl)-1H-1,2,3-triazol-1-yl)pyridine-2,6-
dicarboxylate (11) 
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Product (10) (1.1 eq.; 0.425 mmol; 0.156 g) was dissolved in 10 mL dry DMF and 
N,N-diisopropylethylamine (1.2 eq.; 0.464 mmol; 81 µL) was added to the 
solution. The mixture was stirred for 15 minutes at room temperature under inert 
atmosphere. At the same time, the DTPA tert-butyl ester (1 eq.; 0.25 mmol; 0.156 
g), HATU (1.2 eq.; 0.464 mmol; 0.176 g) were dissolved in a three neck flask in 
10 mL dry DMF and stirred for 15 minutes at room temperature under argon 
atmosphere. Synthetic procedure is analogous to compound (6) yielding yellow oil 
(yield: 0.240 g; 64%). ESI-MS (MeOH, m/z): calcd: 968.11 g/mol [M+H]+, found: 
991 g/mol [M+Na]+. 
Synthesis 2,2',2'',2'''-((((2-((4-(1-(2,6-bis(methoxycarbonyl)pyridin-4-yl)-1H-
1,2,3-triazol-4-yl)benzyl)amino)-2-oxoethyl)azanediyl)bis(ethane-2,1-
diyl))bis(azanetriyl))tetraacetate (12) 
 
Product (11) (1 eq.; 0.284 mmol; 0.240 g) was dissolved in 10 ml of a DCM/TFA 
(50/50) mixture and stirred for 12 h at room temperature. The solvents were 
evaporated and 10 ml of DCM/MeOH (6/4) was added and evaporated and the 
resulting residue was dissolved in pyridine (yield 0.148 g; 70%). 
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General synthesis of methyl protected GdLx 
The methyl protected ligand (1 eq.) was dissolved in 5 mL pyridine and the 
hydrated GdCl3 salt (1.05 eq.) in 0.3 mL water was added to the solution. This 
mixture was stirred for 3 hours at 70 °C. The solvent was removed under reduced 
pressure and ethanol was added. The crude product and the suspension was 
refluxed for 1 hour and filtrated over a P4 glass filter resulting in a pale brown 
solid. The absence of free lanthanide ions was checked by using an arsenazo 
indicator. 
General synthesis of GdLx  
The methyl protected GdLx complex (1 eq.) was dissolved in 5 mL of water and 
K2CO3 (2.5 eq.) was added to the solution. The mixture was stirred overnight at 
room temperature. After the reaction, a pH of about 9 was monitored. The solvent 
was evaporated, water was added and it was stirred for 30 minutes whereby the 
pH changed to circa 8. The solvent was removed under reduced pressure and 
orange flakes were obtained (GdL2: 0.11 mmol; 95%; GdL3: 0.09 mmol; 55%).  
General Synthesis of (GdL2)3Ln.  
The deprotected ligand GdL2 (3 eq.; 51 mg; 0.06 mmol) was dissolved in 3 mL of 
water. The appropriate LnCl3·xH2O (1.1 eq.; 0.02 mmol) was added and the 
reaction was kept at 70 °C for 3 hours. The solvent was removed under reduced 
pressure and ethanol was added. The suspension was refluxed for 1 hour and 
filtered over a P4 glass filter. The complexes have been characterized by TXRF 
spectrometry, IR and optical spectroscopy. The IR spectrum of the ligands show a 
strong absorption in the IR region around 1600 cm-1 which corresponds to the 
C=O bond. After complexation a new peak appears around 1500 cm-1. The Gd/Ln 
ratio obtained via TXRF spectrometry is the following: 3.0 (Gd/Tb), 3.0 (Gd/Dy), 
3.0 (Gd/Eu), 2.9 (Gd/Sm), 2.7 (Gd/Nd), 3.0 (Gd/Yb).  
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CHAPTER 4 
T2 Contrast Agents based on 
iron oxide nanoparticles 
functionalized with  
BODIPY dyes 
This chapter is based on a submitted manuscript: 
“Luminescent and Relaxometric Properties of BODIPY derivatives 
covalently bond to iron oxide nanoparticles as potential bimodal contrast 
agents”, Matthias Ceulemans, Maarten Bloemen, Charlotte Verstraete, Bella 
Manshian, Uwe Himmelreich, Thierry Verbiest, Wim M. De Borggraeve and 
Tatjana N. Parac-Vogt. 
 
 
Synthesis and functionalization of the nanoparticles were done by Dr. Maarten 
Bloemen. Two photon fluorescence imaging was done by Dra. Charlotte 
Verstraete. Cell viability studies and MRI results were done by Dr. Bella 
Manshian and Prof. Uwe Himmelreich. BODIPY synthesis and spectroscopic data 
was recorded by Drs. Matthias Ceulemans. 
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1 Introduction 
Superparamagnetic nanoparticles have attracted a lot of attention due to their 
unique magnetic properties. For example, iron oxide particles are frequently used 
in hyperthermia, optical or drug carrier experiments and MRI.1–5 A well known 
and frequently used material for MRI are the superparamagnetic iron oxide 
particles, which induce inhomogeneties in the local magnetic field and make them 
very efficient T2 MRI contrast agents.6 By combination of iron oxides with an 
organic luminophore, one can obtain a bimodal probe which has a very good 
spatial resolution and high sensitivity.7–11  
A class of organic luminophore are BODIPY dyes, which are small organic 
molecules with generally very high extinction coefficients, fairly sharp 
fluorescence peaks and high quantum yields.12,13 BODIPY derivatives were 
already used in a variety of applications such as electroluminescent devices, 
tunable laser dyes and fluorescent switches.14 Their biological applications are 
found as labels for proteins15,16 and DNA.17,18 
The combination of BODIPY derivatives covalently bound to iron oxide particles 
remains scarce. Few examples are known but they suffer from large size11 or a low 
emission wavelength.10 In this chapter three novel BODIPY derivatives are 
developed that can be covalently attached to ultrasmall iron oxide nanoparticles 
via siloxane chemistry. The BODIPY dyes are introduced onto the particles 
surface during a single functionalization step, thus eliminating post-
functionalization procedures. Moreover, it is advantageous that the dye can be 
embedded into a ligand shell, which is protecting it from the environment and 
reduces possible adverse effects of experimental conditions. The addition of 
stabilizing ligands such as siloxane-PEG improves the water dispersibility and 
biocompatibility of the IO NPs.19 The convenient synthesis of siloxane coated iron 
oxide particles as potential bimodal contrast agent for MRI and optical imaging 
can have broader applicability as the developed procedure provides an efficient 
and straightforward methodology for grafting different BODIPY derivatives onto 
a nanoparticle surface in general.20  
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2 Results and discussion 
2.1 Ligand design and synthesis 
The strategy to synthesize small monodisperse multimodal iron oxide 
nanoparticles (NPs) is depicted in Scheme 4.1. Oleate capped iron oxide NPs are 
synthesized according to literature procedure by Park et al.21 The covalent 
functionalization of these NPs utilizes an optimized synthetic procedure by 
Bloemen et al.20 The synthetic approach to the BODIPY derivatives is a 
straightforward two-step reaction, which will lead to the BODIPY core. 
BODIPY(CH2)2CH=CH2 (BDP1) was previously reported by Esfandiari et al.22 
and was synthesized using a slightly altered method. Reaction of 4-pentenoyl 
chloride with two equivalents of 2,4-dimethylpyrrole and subsequent 
complexation with boron trifluoride diethyl etherate gives BDP1 in a good yield 
(Scheme 4.2). The double bond implemented in the meso position of the BODIPY 
core allows easy covalent attachment to the ultrasmall iron oxide nanoparticles. 
The emission wavelength of BODIPY derivatives can be tuned by increasing the 
electron resonance of the core structure. Tissue penetration is a very important 
factor in choosing the emission wavelength of the luminophore. A good trade-off 
between image resolution and penetration depth can be made in the region 
between 665 to 900 nm, the so-called biological window.23 A selective 
Knoevenagel condensation of the methyl arms was used to further modify the 
BODIPY core. Addition of an appropriate aldehyde to BDP1 gave the desired 
products (BDP2 and BDP3) after a reaction time of only 1 h at 80 °C (Scheme 
4.2). 
 
Scheme 4.1. Schematic representation of the synthesized iron oxide NPs. The oleate 
capped iron oxide NPs were treated with the appropriate ratio of siloxanes to obtain 
the different NPs: NP-BDP1, NP-BDP2 and NP-BDP3. 
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Scheme 4.2. Synthetic pathway to synthesize the desired BODIPY derivatives: a) R.T., 
30 min → reflux, overnight b) triethylamine, BF3·Et2O, 0 °C, 5 min → R.T., overnight, 
c) molecular sieves, pyrrolidine, acetic acid, 80 °C, 1 h. 
The allyl bond of the BODIPY dye allows for conversion with (3-mercaptopropyl) 
trimethoxysilane via thiolene click chemistry (Scheme 4.3).24 The final hybrid IO 
NPs are obtained by reacting BODIPY-siloxane (1%) with a PEG10-siloxane 
(99%) in presence of a base and the IO NPs. The PEG10 chains are used in order to 
ensure water dispersibility and biocompatibility of the NPs.24 Using an increased 
concentration of 5% BODIPY-siloxane to 95% PEG10-siloxane was also 
attempted, but the final particles were not stable in aqueous solutions, most likely 
due to the apolar nature of the BODIPY derivative. Therefore, a ratio of 1% was 
kept for further studies, as a good trade-off between good fluorescence and water 
dispersibility. Due to the apolar nature of BDP2, the straightforward grafting onto 
the IO particle has proven to be more difficult as the resulting NPs were not water 
dispersible. By using 4-(2-hydroxyethoxy)benzaldehyde instead of benzaldehyde, 
the BODIPY core was made more polar and the resulting BDP3 could easily be 
grafted onto the surface of NPs resulting in a water dispersible product. Despite 
the incompatibility of BDP2 with aqueous environments, this derivative was 
attached to NPs generating a NP-BDP2 hybrid which is dispersible in apolar 
solvents. Such hybrid could be potentially useful for applications in apolar media, 
such as polymer blends or for thin film production.  
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Scheme 4.3. Synthetic procedure for the functionalization of iron oxide NPs. a) 5% 
2,2-Dimethoxy-2-phenylacetophenone, chloroform, UV, 0.5-1 h. b) triethylamine, 
toluene, sonication, 5 h. 
 
 
Figure 4.1. An overview of the novel BODIPY derivatives used. 
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2.2 Photophysical properties 
The final obtained BODIPY derivatives are strongly colored solids with a slight 
metallic luster, which in solution gave a strong fluorescence upon irradiation. The 
electronic absorption and emission spectra of BDP1, BDP2 and BDP3 are shown 
in Figure 4.2, and exhibit the characteristic narrow absorption bands. The main 
absorption bands show maximum λabs(max) at 502, 618 and 639 nm for BDP1, 
BDP2 and BDP3 respectively. This visible absorption band is assigned to the 
S0→S1 transition. Additional, considerable weaker, broad absorption bands were 
also observed in the UV-Vis region at ca. 350 nm, and is attributed to the S0→S2 
transition (not shown).25 Although the absorption spectra show great similarities, 
the emission patterns are quite different, due to the substituents on the 3 and 5 
position of the BODIPY core. The emission maximum λem(max) of BDP1 was 
observed at 538 nm, which results in a Stokes shift of 36 nm. The emission 
spectrum of BDP2 shows two emission maxima at 651 and 690 nm, while the two 
maxima for BDP3 were observed at 680 and 712 nm. It is therefore evident that 
introduction of an ethylene glycol moiety into the BODIPY core of BDP3, gives 
rise to a red shift of 21 nm in comparison with BDP2. 
 
Figure 4.2. Normalized absorbance (left) and emission spectrum (right):  
BDP1 (CHCl3, λex = 480 nm, full line), BDP2 (CHCl3, λex = 580 nm, dashed line)  
and BDP3 (CHCl3, λex = 580 nm, dotted line). 
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 The absorbance spectrum of NP-BDP show the distinct exponential curve of 
Rayleigh scattering as expected from such small particles, but clear absorption 
maxima can be distinguished (Figure 4.3). The excitation spectra are shown in 
grey. The absorption maximum λabs(max) of NP-BDP1 is the same as for the free 
BDP1 dye and is observed at 502 nm. A shift in λabs(max) was however observed 
for NP-BDP2 (from 618 to 515 nm) and NP-BDP3 (from 639 to 518 nm) upon 
attachment to the NP core. These shifts are most likely result of aggregation of 
BODIPY derivatives onto the surface of NP due to π-π stacking. Upon excitation 
at 480 nm the emission maximum λem(max) of NP-BDP1 was observed at 538 nm. 
An emission signal was observed for NP-BDP2 at 594 nm with the broad 
shoulder, while NP-BDP3, exhibited two maxima at 613 and 661 nm, upon 
excitation at 580 nm. The NP-BDP2 and NP-BDP3 exhibit therefore large Stokes 
shifts of 78 nm and 95 nm respectively. 
 
Figure 4.3. Normalized absorbance and excitation (left) and emission spectrum 
(right): NP-BDP1 (H2O, λem = 525 nm, λex = 480 nm, full line), NP-BDP2 (CHCl3, λem = 
610 nm, λex = 500 nm, dashed line), and NP-BDP3 (H2O, λem = 660 nm, λex = 500 nm, 
dotted line). 
In addition to one-photon fluorescence, all NP-BDPs also showed interesting 
characteristics for two-photon fluorescence. Two-photon experiments were carried 
out by dropcasting the NP-BDPs on a glass plate and visualizing them under a 
multiphoton microscopy at a fundamental wavelength of 1100 nm and a 15X 
magnification. NP-BDP3 showed a strong increase in two-photon fluorescence 
compared to the iron oxide NPs without BODIPY (Figure 4.4). This interesting 
feature offers potential application for multimodal imaging in addition to MRI. It 
T2 Contrast Agents based on IONP functionalized with BODIPY dyes| 
 
84 
has been shown that multiphoton microscopy can be used for in vivo experiments 
with high penetration depths, but the lack of contrast and the difficult 
administration of fluorophores hampers research.26 For cancer research, iron oxide 
NPs can be used to target the tumors, since the particles will automatically 
accumulate in these cells due to passive targeting.27 Therefore, NP-BDPs may be 
suitable for increasing contrast in tumors in vivo, which would lead to a reduction 
of the minimum laser power, thus resulting in less tissue damage. 
 
Figure 4.4. Two-photon fluorescence image of NP-BDP3 under a 
multiphoton microscopy at a fundamental wavelength of 1100 nm and 
a 15X magnification. 
2.3 Relaxivity studies 
To assess the relaxivity of the iron oxide nanoparticles different concentrations of 
nanoparticles were homogenously suspended in an agar phantom (Figure 4.5) and 
the relaxivity values of the iron oxide nanoparticles were calculated from a 
parametric map (Table 4.1). A clear increase in relaxivity can be observed at 
higher concentrations of iron oxide nanoparticles. As expected, the relaxivities r1 
and r2 of the bare nanoparticles and the functionalized nanoparticles do not differ 
greatly. Values of r2 of 52 ± 5 s-1mM-1 for the bare NPs and 49 ± 3 s-1mM-1, 47 ± 7 
s-1mM-1 are obtained for NP-BDP1 and NP-BDP3, respectively. Furthermore, 
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human ovarian cancer (SKOV3) cells were labeled with the NPs to validate the 
potential to visualize them by MRI. T2*-weighted MR images of labeled and 
unlabeled cells are shown in Figure 4.5. A clear contrast increase is observed in 
the tube with the labeled cells. 
Table 4.1. Relaxivities of iron oxide nanoparticles functionalized without and with 
BODIPY dyes (NP-BDP1 and NP-BDP3). Relaxivities were determined in agar 
phantoms using various concentrations of the respective nanoparticles (Figure 4.5) 
and were calculated from a parametric map. 
 
r1 [s-1mM-1] r2 [s-1mM-1] 
Bare NP 1.21 ± 0.10 52 ± 5 
NP-BDP1 1.12 ± 0.15 49 ± 3 
NP-BDP3 1.15 ± 0.10 47 ± 7 
 
Figure 4.5. Color-coded T2 and T1 relaxivities maps of nanoparticles 
suspended in agar phantoms using various concentrations of nanoparticles. 
Gray-colored T2*-weighted images of (a) unlabeled and (b) labeled human 
ovarian cancer (SKOV3) cells suspended in agar. The arrow indicates hypo-
intense areas in the MRI due to NP-labeled cells. The total amount of cells 
was 105 ml-1. 
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2.4 Cell viability studies 
In order to assess the biocompatibility of the nanoparticles, the toxic effects of the 
NP-BDP3 particles were assessed with a previously validated high-content image 
based screening approach,28 where effects of NPs on cell viability and alterations 
in cell morphology were evaluated. The data show a clear cell type dependent 
difference in cytotoxicity from cellular exposure to the NP-BDP3 (Figure 4.5). 
The rat tumor (AR42J) and human ovarian cancer (SKOV3) cells showed no 
significant cytotoxicity following exposure to the NPs at any of the tested 
concentrations. Human hepatic stellate (GRX) cells were only significantly 
affected by the NPs at the highest concentrations (100 and 200 µg/ml). Contrary to 
these cell types, human umbilical vein (HUVEC) and rat insulinoma (INS1) cells 
demonstrated a high sensitivity to the NP-BDP3, with significant cell death noted 
in both cell types starting from the lower 5 and 10 µg/ml concentrations 
consecutively. The effects of the NPs in these cells on cellular survival were most 
drastic at 50 µg/ml concentration and above where cell survival reached down to 
approximately 50% and lower with the increase in the exposure level.  
 
Figure 4.6. Cell viability results of AR42J, SKOV3, GRX, HUVEC, and INS1 
cells exposed to various concentrations of NP-BDP3 for 24 h. Results 
represent quantitative data for the analysis of a minimum of 2000 cells per 
condition. Quantitative data are presented as mean + SEM (n = 3) for NP-
treated cells relative to untreated control cells (± 100%). The degree of 
statistical significance is shown when appropriate (*: p < 0.05, **: p < 0.01, 
***: p < 0.001). 
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3 Conclusions 
In this paper the synthesis and characterization of small monodisperse multimodal 
iron oxide nanoparticles, functionalized with three types of boron-dipyrromethene 
(BODIPY) derivatives has been reported. Three BODIPY derivatives, BDP1, 
BDP2, and BDP3 were covalently attached to iron oxide nanoparticles via thiolene 
click chemistry. All three hybrids showed absorption maxima in the range of 500-
540 nm, which could be clearly distinguished within the absorption spectrum 
dominated by Rayleigh scattering. Upon excitation, bright green and red 
fluorescence at 538, 594, and 661 nm was observed for NP-BDP1, NP-BDP2, and 
NP-BDP3 respectively. Interestingly, NP-BDP3 showed a strong increase in two-
photon fluorescence compared to the iron oxide NPs with no BODIPY. Relaxivity 
studies on agar phantoms showed an r2 value of 49 ± 3 and 47 ± 7 s-1mM-1 for NP-
BDP1 and NP-BDP3 respectively. Cell viability studies on rat tumor (AR42J) and 
human ovarian cancer (SKOV3) cells showed no significant cytotoxicity at any of 
the tested concentrations. Human hepatic stellate (GRX) cells were only 
significantly affected by the NPs at the highest tested concentrations, 100 and 200 
µg/ml. 
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4 Experimental section 
Synthesis of BODIPY(CH2)2CH=CH2 (BDP1) 
   
This molecule was synthesized according to an altered synthesis of Esfandiari et 
al.22 To a solution of 4-pentenoyl chloride (1 eq.; 4.86 mmol; 0.536 mL) in 25 mL 
dry DCM was added 2,4-dimethylpyrrole (2 eq.; 9.71 mmol; 1 mL). And the 
solution was stirred for 30 minutes at room temperature. The color changed from 
yellow to red-brown. Phosphoryl chloride (1.1 eq.; 5.35 mmol; 0.500 mL) was 
slowly added and the solution was refluxed overnight. The solution was then 
cooled to 0 °C and triethylamine (10 eq.; 49 mmol; 6.8 mL) was added. After 5 
minutes of stirring at 0 °C boron trifluoride diethyl etherate (11 eq.; 53 mmol; 6.6 
mL) was slowly added and the solution was stirred at room temperature overnight. 
Diethyl ether (100 mL) was added to the solution and the organic layer was 
washed with water (3x 50 mL). The organic layer was dried with MgSO4 and 
concentrated in vacuo. The resulting residue was purified using silica column 
(eluent: DCM/PET 50:50) yielding an orange solid (yield: 0.639 g, 43%). ESI-MS 
(MeOH, m/z): calcd: 325.18 g/mol [M+Na]+, found: 325.8 g/mol [M+Na]+. 1H 
NMR (400 MHz, CDCl3, δ ppm): 2.34-2.39 (m, 2H), 2.41 (s, 6 H), 2.53 (s, 6H), 
3.03-3.07 (m, 2H), 5.09-5.19 (m, 2H), 6.07 (s, 2H); 13C NMR (100 MHz, CDCl3, δ 
ppm): 14.43, 14.45, 16.28, 27.07, 35.24, 115.62, 121.68, 131.39, 140.41, 145.43, 
153.97. 
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Synthesis of BDP2 (2) 
   
BDP1 (1 eq.; 0.25 mmol; 75 mg) was dissolved in dry ACN (12 mL) under argon 
atmosphere and 4 Å molecular sieves were quickly added. Then benzylaldehyde 
(5 eq.; 1.28 mmol; 0.130 mL), pyrrolidine (6 eq.; 1.5 mmol; 0.125 mL) and glacial 
acetic acid (6 eq.; 1.5 mmol; 0.086 mL) were added under argon atmosphere. The 
reaction was immersed in a pre-heated 80 °C oil bath and in a few minutes the 
color turned blue. The reaction was followed with TLC (eluent: DCM/PET 50:50 
RF: 0.43) until full conversion of the starting product, which took about an hour. 
The mixture was cooled to room temperature and 40 mL DCM/diethyl ether (1:2) 
was added. The organic layer was washed with a 0.05 M HCl solution (2x 40 mL), 
saturated NaHCO3 (20 mL), brine (20 mL). The organic layer was dried over 
MgSO4 and reduced to dryness in vacuo. The residue was purified using silica 
column (eluent: DCM/PET 50:50, Rf = 0.43) yielding a purple solid (yield: 36 mg, 
30%). ESI-MS (MeOH, m/z): calcd: 480.38 g/mol [M+H]+, found: 979.4 g/mol 
[2M+Na]+. 1H NMR (400 MHz, CDCl3, δ ppm): 2.38-2.45 (m, 2H), 2.50 (s, 6 H), 
3.10-3.14 (m, 2H), 5.12-5.22 (m, 2H), 5.95-6.01 (m, 1H), 6.74 (s, 2H), 7.28-7.44 
(m, 8H), 7.64-7.77 (m, 8H); 13C NMR (100 MHz, CDCl3, δ ppm): 16.6, 27.1, 35.5, 
115.7, 118.4, 119.3, 127.5, 128.7, 128.8, 133.3, 135.8, 136.4, 136.7, 139.7, 142.7, 
151.5. 
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Synthesis of BDP3 (3) 
   
Synthesis of BDP3 is analogous to BDP2, but 4-(2-hydroxyethoxy)benzaldehyde 
is used. The residue was purified using silica column (eluent: EtOAc, Rf = 0.30) 
yielding a purple solid (yield: 30 mg, 20%). ESI-MS (MeOH, m/z): calcd: 599.49 
g/mol [M+H]+, found: 600.0 g/mol [M+H]+. 1H NMR (400 MHz, CDCl3, δ ppm): 
2.39-2.46 (m, 2H), 2.51 (s, 6 H), 3.12-3.16 (m, 2H), 4.00-4.02 (m, 4H), 4.14-4.17 
(m, 4H), 5.12-5.23 (m, 2H), 5.94-6.01 (m, 1H), 6.72 (s, 2H), 6.97-7.44 (d, J = 8.7, 
4H), 7.20-7.24 (d, 2H), 7.58-7.60 (d, 4H); 7.58-7.63 (d, J = 17, 2H); 13C NMR 
(100 MHz, CDCl3, δ ppm): 16.6, 27.1, 29.7, 35.6, 61.4, 69.3, 114.9, 115.7, 117.5, 
118.1, 129.0, 130.1, 135.2, 136.5, 139.4, 141.7, 151.6, 159.3. 
Thiolene click chemistry  
To form the siloxane-terminated molecule, an allyl terminated molecule (mixture 
of allyl-PEG and allyl-BODIPY, total 1 mmol) was mixed with (3-
mercaptopropyl) trimethoxysilane (1 eq.; 1 mmol; 185.7 mL) and 2,2-dimethoxy-
2-phenylacetophenone (DMPAP, 0.05 eq.; 0.05 mmol; 12.8 mg). This mixture 
was stirred for 1 hour in a UV chamber, equipped with 3 LEDs (365 nm, output 
power 200 mW). If smaller quantities are used, a small amount of chloroform can 
be added to improve the stirring. The product was used without further 
purification.  
  
| Chapter 4 
 
91 
Nanoparticle functionalization 
The synthesis of iron oxide NP as well as functionalization with siloxanes onto 
their surface was performed as reported in ref. 20 and is reported here for 
convenience. In general, 1 mmol of siloxanes is mixed with 100 mg of IONP in 50 
mL of toluene. To this mixture 2.5 mL of triethylamine and 50 µL of water are 
added. The solution was placed in an ultrasonication bath for 5 hours, after which 
50 mL of heptane was added to precipitate the particles. Afterwards, they were 
attracted magnetically and washed 3 times with acetone. Finally the particles were 
dried in vacuum and dispersed in MilliQ water (with a concentration up to 20 
mg/mL). 
 
 
Figure 4.7. IR data of the synthesized BODIPY derivatives (red)  
and the nanoparticles (black). 
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Figure 4.8. TEM image of the oleate capped NPs. The average size is 8.6 ± 0.6 nm. 
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CHAPTER 5 
Gd-DOTA functionalized with 
BODIPY dye as a potential  
T1 contrast agent  
This chapter is based on a manuscript in published in Inorganics, 2015, 3, 516-
533. 
“Gadolinium(III)-DOTA complex functionalized with BODIPY as a potential 
bimodal contrast agent for MRI and optical imaging”, Matthias Ceulemans, 
Koen Nuyts, Wim M. De Borggraeve, and Tatjana N. Parac-Vogt. 
 
 
 
In this chapter the synthesis and characterization of a novel gadolinium(III)-
DOTA complex functionalized with a boron-dipyrromethene (BODIPY) 
derivative is described. The assembly of the luminescent complex relies on azide 
diazotransfer chemistry in a copper tube flow reactor with subsequent click 
chemistry. Optimization of the flow reaction was done by Dr. Koen Nuyts and 
reported in a paper.1 The synthesis and characterization of the luminescent 
complex was done by Drs. Matthias Ceulemans. Gratitude goes towards Prof. 
Koen Binnemans for TXRF measurements and to Prof. Luce Vander Elst of the 
University of Mons for the relaxometric data.   
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1 Introduction 
As mentioned in previous chapters, a promising class of organic dyes to 
synthesize bimodal MRI contrast agents are 4,4-difluoro-4-bora-3a,4a-diaza-s-
indacene (abbreviated as BODIPY) and its derivatives. This class of organic 
molecules generally has very high extinction coefficients, fairly sharp 
fluorescence peaks and high quantum yields. The BODIPY core is fairly stable 
under physiological conditions and relatively insensitive to the environment. Their 
emission wavelength is tunable by increasing the resonance within the BODIPY 
core.2 The BODIPY dyes have been used in a variety of applications such as 
biological labels and probes,3–5 fluorescent probes,6 laser dyes,7,8 light emitting 
diodes,9 solar cells,10,11 and potential sensitizers in photodynamic therapy.12,13 
The first potential bimodal imaging agent for optical and nuclear imaging 
(PET/CT) consisting of a DOTA ligand and functionalized with a BODIPY 
compound was reported in 2010 by Bernhard et al.14 In 2012 the same group 
expanded their compound to a DOTAGA derivative (GA = glutaric acid) which 
gives more stable complexes with the transition metals.15 Considering the 
versatility and favorable optical properties of BODIPY organic dyes, there are 
surprisingly very few examples of its use as an optical probe in the development 
of bimodal contrast agents. In previous work primary amines are converted into 
azides functionalized in a copper tube flow reactor. These azides were used in a 
subsequent copper mediated cycloaddition using the copper catalyst generated in 
situ from the metallic copper.1 This chapter further expands this strategy for 
performing azide-alkyne cycloaddition in order to create a Gd-DOTA-BODIPY 
derivative. The synthesis and characterization of this novel compound and 
evaluation of its potential as a bimodal contrast agent for MRI and optical imaging 
is investigated.   
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2 Results and Discussion 
2.1 Ligand design and synthesis  
The main concept used in order to create a Gd-DOTA-BODIPY derivative is 
based on using click chemistry to couple a BODIPY dye to a DOTA moiety. The 
resulting bimodal agent with both optical and paramagnetic entities, 5,5-difluoro-
1,3,7,9-tetramethyl-10-(2-(4-((2-gadolinium(III)-(4,7,10-tris(carboxylatomethyl)-
1,4,7,10-tetraazacyclododecan-1-yl)acetamido)methyl)-1H-1,2,3-triazol-1-
yl)ethyl)-5H-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-4-ium-5-uide, is presented 
in Figure 5.1. 
 
Figure 5.1. The synthesized Gd-DOTA-BODIPY derivative. 
The synthesis of the BODIPY core starts with the protection of β-alanine with 
phthalic acid in solvent free conditions. Subsequent reaction with thionyl chloride 
converts the acid group into an acid chloride, which can react further with two 
equivalents of 2,4-dimethylpyrrole to form a dipyrromethene derivative. 
Complexation of this product with borontrifluoride dietherate and a base forms 
BODIPY-(CH2)2-phthalimide. This product can easily be transformed into 
BODIPY-(CH2)2-amine by using hydrazine in ethanol, which was clearly 
demonstrated by the disappearance of the aromatic peaks at 7.77 and 7.88 ppm, 
and appearance of a new peak at 1.61 ppm in the 1H NMR spectrum (Scheme 5.1). 
The final BODIPY product contains an amine function which can be transformed 
in a copper tube into an azide via a diazotranfer reagent (ISA·H2SO4) giving 
BODIPY-(CH2)2-azide shown in Figure 5.2a.16,17 
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Scheme 5.1. Synthetic procedure for BODIPY-(CH2)2-amine: a) 160 °C, 6 h; b) SOCl2, 
reflux, 3 h; c) 2 eq. 2,4-dimethylpyrrole, DCM, 0 °C → reflux, 4 h; d) 10 eq. DIPEA, 
11 eq. BF3·Et2O, DCM, 0 °C → R.T., overnight; e) N2H4·H2O, EtOH, reflux, 3 h. 
The propargylated Ln-DOTA complex (Ln = La(III), Gd(III)) that was used for 
coupling to BODIPY dye is shown in Figure 5.2b.18,19 The coupling was 
performed by using a flow chemistry approach, which can mitigate some safety 
related issues regarding working with azides.20 Organic azides can be synthesized 
from primary amines via a diazotransfer reaction. Trifluoromethanesulfonyl azide 
is most commonly used as a diazotransfer reagent.21 The potential short shelf life 
and highly explosive nature requires careful consideration of the safety issues for 
their handling.22 Some safety issues can be circumvented by introduction of 
imidazole-1-sulfonyl azide (ISA) or its hydrogen sulfate salt (ISA·H2SO4).16,23 The 
flow reaction was performed by mixing solutions of BODIPY-(CH2)2-amine and 
ISA·H2SO4, which is graphically represented in Scheme 5.2. Upon leaving the 
reactor, the reaction mixture was directly added to a solution of propargylated Ln-
DOTA (Ln = La(III) or Gd(III)), resulting in the final product Ln-DOTA-
BODIPY.  
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Figure 5.2. a) Structure of BODIPY-(CH2)2-azide made in a copper tube 
reactor. b) Structure of propargylated Gd(III)-DOTA complex used to couple 
to the azide. 
 
Scheme 5.2. Schematic representation of the flow reactor. 
The Ln-DOTA-BODIPY complexes have been isolated, purified and the 
diamagnetic lanthanum(III) complex La-DOTA-BODIPY has been characterized 
by 1H NMR spectroscopy in solution (Figure 5.3). The 1H NMR spectrum shows a 
distinct peak of the triazole proton at 7.55 ppm and two protons on the BODIPY 
core at 6.00 ppm, indicating a successful linkage of the DOTA moiety with the 
BODIPY derivative. The 1H NMR spectrum also shows broad peaks in the region 
from 2.20-3.82 ppm which are typical for the protons in the DOTA ring.24  
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Figure 5.3. 1H NMR spectrum of the final clicked La-DOTA-BODIPY derivative 
measured in deuterated water. The protons of the triazole ring (7.55 ppm) and of the 
BODIPY core (6.00 ppm) are clearly visible indicating a successful linkage of the 
DOTA moiety with the BODIPY derivative. 
2.2 Photophysical properties 
The solid of this BODIPY derivative is strongly red colored. BODIPY derivatives 
are apolar in nature and dissolve very well in apolar organic solvents, like 
chloroform or dichloromethane, and will emit bright green fluorescence. Due to 
the coupling to hydrophilic Ln-DOTA complex, the final Ln-DOTA-BODIPY 
adducts are water soluble and give bright green fluorescence in aqueous solution, 
as is depicted in Figure 5.4, where an aqueous solution of the synthesized Gd-
DOTA-BODIPY in the absence and presence of excitation at 366 nm is shown 
Figure 5.4. Furthermore, the figure shows the electronic spectra of Gd-DOTA-
BODIPY and depicts the characteristic and rather narrow absorption and emission 
bands typical for BODIPY dyes. A main absorption band (dotted line) with a 
maximum λabs(max) at 503 nm is observed for Gd-DOTA-BODIPY in aqueous 
solution. Absorption maxima of 507 and 502 nm were recorded for BODIPY-
(CH2)2-phthalimide and BODIPY-(CH2)2-amine respectively. The visible 
absorption bands can be assigned to the S0→S1 transition.25 An additional, 
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considerably weaker broad absorption band is observed in the UV-Vis region 
around 360 nm, and is attributed to the S0→S2 transition. It should be noted that 
the optical properties of the BODIPY dyes can be tuned by increasing conjugation 
by placing different substituents on the BODIPY core. Such substitutions increase 
the resonance of the whole structure and provide a red shift of the main emission 
band, which is favorable for biological applications. A tradeoff between tissue 
penetration and image resolution for in vivo imaging can be made in the optical 
imaging window (from 665 to 900 nm).26 In this region the extinction coefficients 
of the main sources of absorption, hemoglobin, deoxyhemoglobin, and water, are 
at their minimum. However, it must be taken into account that placing additional 
substituents on the BODIPY usually renders the system more hydrophobic and 
decreases the solubility of the entire complex in water. The emission maximum 
(λex = 490 nm, H2O) of Gd-DOTA-BODIPY is observed at 523 nm, and is in 
accordance with the previously reported BODIPY derivatives.27 The excitation 
maximum (λem = 570 nm, H2O) shows a peak at 503 nm. (Figure 5.4)  
 
Figure 5.4. Absorption (dotted line), emission (λex = 490 nm, black line) and excitation 
(λem = 570 nm, dashed line) spectra of Gd-DOTA-BODIPY in water. An aqueous 
solution of Gd-DOTA-BODIPY in the absence and presence of excitation at 366 nm. 
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The fluorescent quantum yields QL of La-DOTA-BODIPY and Gd-DOTA-
BODIPY were determined upon ligand excitation by a comparative method, using 
a solution of Rhodamine 6G (Q = 78%)28 in water as the standard. The advantage 
of BODIPY dyes is that the quantum yields of their derivatives are generally high, 
even in water.6 The quantum yield was determined according to the following 
equation: 
𝑄𝐿 = 𝑄𝑆 ∙ 𝐼𝑋𝐼𝑆 ∙ 𝐴𝑆(𝜆𝑒𝑥𝑐)𝐴𝑋(𝜆𝑒𝑥𝑐) ∙ 𝜂𝑋2𝜂𝑆2 (eq. 5.1) 
In this equation the s and x refer to the standard and the unknown sample 
respectively, I represents the corrected total integrated emission intensity, A the 
absorbance at the excitation wavelength, η the refractive index of the solution 
(ηwater = 1.34) and Qs the quantum yield of the standard. The samples are diluted 
until the absorbance at the excitation wavelength is between 0.02–0.05. Quantum 
yields are recorded with ligand excitation wavelength of 490 nm and gave values 
of 80% and 83% for La-DOTA-BODIPY and Gd-DOTA-BODIPY respectively. 
2.3 Relaxivity measurements 
The relaxivity r1 is the efficiency of a 1 mM solution of gadolinium(III) agent to 
shorten the longitudinal relaxation time (T1). According to the Solomon 
Bloembergen Morgan theory29,30 several parameters can alter the relaxivity of a 
contrast agent. High relaxivity can be obtained with a higher amount of water 
molecules directly bound to the paramagnetic centre (q). Although an easy 
parameter to adjust, increasing the q value leads to less stable complexes. Other 
parameters are the distance between gadolinium(III) and water (r), the water 
residence time (τM), the rotational correlation time of the paramagnetic centre (τR), 
the electronic relaxation time of gadolinium(III) at zero field (τS0) and the 
correlation time modulating the electronic relaxation (τv). The relaxivity of Gd-
DOTA-BODIPY derivative measured at frequencies of 20 and 60 MHz at 310 K 
and was found to be 3.9 and 3.6 s-1mM-1 respectively. These values are in close 
comparison with previously reported values for Gd-DOTA complex, which gave 
values of 3.5 and 3.1 s-1mM-1 at 20 and 60 MHz respectively.31 A slight increase 
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compared to the parent Gd-DOTA complex can be attributed to the higher 
molecular weight of the Gd-DOTA-BODIPY complex, resulting in a slower 
rotational correlation rate and an overall increase of the relaxivity. The limiting 
factors for the increase of Gd-DOTA-BODIPY relaxivity are probably the 
presence of an amide bond in the DOTA scaffold which may slow down the water 
exchange rate, or flexible linker used for attaching the BODIPY core to the DOTA 
moiety, which may result in high internal rotations within the Gd-DOTA-
BODIPY complex. 
3 Conclusions 
In this chapter a novel Gd-DOTA-BODIPY derivative is synthesized via a 
diazotransfer reaction under flow conditions in a copper tube. The complex is 
water-soluble and exhibits favorable fluorescent properties, thus offering the 
possibility for the use of BODIPY adducts for in vivo optical imaging. A high 
quantum yield of 83% is obtained in water, and bright emission was observed at 
523 nm. Shifting of the emission to the more optimal red-IR region of the 
spectrum will be attempted in future by increasing the electronic resonance of the 
BODIPY by adding appropriate substituents to the BODIPY core. The complex 
exhibits relaxivities which are comparable to the parent Gd-DOTA complex and 
therefore holds potential as a bimodal contrast agent for MRI and optical imaging. 
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4 Experimental section  
Synthesis of 3-(1,3-dioxoisoindolin-2-yl)propanoic acid (1) 
 
Phthalic anhydride (1 eq.; 40 mmol; 5.92 g) and β-alanine (1 eq.; 40 mmol; 3.56 
g) were added in a round bottom flask and heated up to 160 °C for 6 h where it 
became a smelt. The mixture was cooled and the resulting solid was dissolved in 
DCM. The solution was washed with 0.1 M HCl (3x 30 mL). The organic layer 
was dried with MgSO4 and evaporated till dryness as a white solid. (yield: 5.68 g, 
25.9 mmol, 65%). CI-MS (MeOH, m/z): calcd: 219.19 g/mol, found: 220.0 g/mol 
[M+H]+. 1H NMR (300 MHz, CDCl3, δ ppm): 2.80 (t, J=7.4 Hz, 2H), 4.00 (t, 
J=7.4 Hz, 2H), 7.74 (m, 2H), 7.84 (m, 2H); 13C NMR (75 MHz, CDCl3, δ ppm): 
32.8, 33.4, 123.4, 132.0, 134.1, 168.0, 176.5.  
Synthesis of BODIPY-(CH2)2-phthalimide (2)  
 
To a round bottom flask product (1) (1 eq.; 5 mmol; 1.10 g) and thionyl chloride 
(5 eq.; 25 mmol; 1.82 mL) were added and refluxed for 3 hours. The thionyl 
chloride was removed in vacuo till dryness. The acid chloride was used further 
without any purification. The yellow residue was dissolved in 30 mL dry DCM 
and 2,4-dimethylpyrrole (2 eq.; 10 mmol; 1.04 mL) was slowly added. The 
solution was stirred for 30 minutes at room temperature. The color changed from 
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yellow to red-brown. The solution was subsequently refluxed for 4 h. The solution 
was then cooled to 0 °C and triethylamine (10 eq.; 50 mmol; 6.97 mL) was added. 
After 5 minutes of stirring at 0 °C boron trifluoride diethyl etherate (11 eq.; 55 
mmol; 6.79 mL) was slowly added and the solution was stirred overnight at room 
temperature. The solution was diluted with diethyl ether (100 mL) and the organic 
layer was washed with water (3x 50 mL). The organic layer was dried with 
MgSO4 and concentrated in vacuo. The resulting residue was purified using silica 
column (eluent: DCM/PET 50:50) yielding a dark orange solid (yield: 0.392 g, 0.9 
mmol, 19%). CI-MS (MeOH, m/z): calcd: 421.25 g/mol, found: 421 g/mol [M]+. 
1H NMR (300 MHz, CDCl3, δ ppm): 2.54 (s, 6H), 2.67 (s, 6H), 3.42 (t, J=8.60 
Hz,2H), 3.89 (t, J=8.60 Hz, 2H), 6.11 (s, 2H), 7.77 (m, 2H), 7.88 (m, 2H); 13C 
NMR (100 MHz, CDCl3, δ ppm): 14.6, 16.4, 27.7, 39.0, 122.2, 123.5, 131.7, 
131.9, 134.3, 139.8, 141.5, 154.9, 168.2. 
Synthesis of BODIPY-(CH2)2-amine (3)  
 
BODIPY-(CH2)2-phthalimide (2) (1 eq.; 0.37 mmol; 158 mg) and hydrazine 
hydrate (1 eq.; 0.37 mmol; 18.8 mg) in 20 mL ethanol was refluxed for 3 h. After 
which the solution was cooled to room temperature and filtrated with a Millipore 
0.45 µM filter and the solvent was concentrated in vacuo as an orange solid (yield: 
0.106 g, 0.36 mmol, 97%). CI-MS (MeOH, m/z): calcd: 291.17 g/mol, found: 282 
g/mol [M-F]+ and 291 [M]+. 1H NMR (300 MHz, CDCl3, δ ppm): 1.61, (broad, 
2H), 2.45 (s, 6H), 2.51 (s, 6H), 2.99 (m, 2H), 3.14 (m, 2H), 6.05 (s, 2H); 13C NMR 
(100 MHz, CDCl3, δ ppm): 10.5, 12.6, 28.2, 40.1, 117.9, 127.8, 136.6, 138.9, 
150.2.  
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Synthesis of DO3A-tBu (4) 
 
The synthesis uses an altered synthesis by Viguier et al.18 To a solution of 
tetraazacyclododecane (1 eq.; 5.80 mmol; 1 g), sodium bicarbonate (3.5 eq.; 20.3 
mmol; 1.71 g) in 150 mL ACN under an argon atmosphere a solution of tert-butyl 
bromoacetate (3.5 eq.; 20.3 mmol; 3.0 mL) in 50 mL ACN was added drop wise. 
The mixture was refluxed for 17 h. After removing the salts via filtration over 
Celite® the solvent was evaporated and the solid was recrystallized from toluene 
as a white powder (yield: 2.47 g, 4.8 mmol, 82%). ESI-MS: m/z calcd 516 
[M+H]+, 538 [M+Na]+, found 516.0 [M+H]+, 537.5 [M+Na]+. 1H NMR (CDCl3, 
300 MHz, δ ppm): 1.46 (s, 27H), 2.88 (t, 12H), 3.08 (t, 4H), 3.30 (s, 2H), 3.38 (s, 
4H); 13C NMR (CDCl3, 75 MHz, δ ppm): 28.2, 28.3, 47.5, 49.5, 51.3, 58.1, 81.6, 
81.7, 169.8, 170.6. 
Synthesis of {4,10-Bis-tert-butoxycarbonylmethyl-7-[(2-propynylcarbamoyl)-
methyl]-1,4,7,10-tetraaza-cyclododec-1-yl}-acetic acid tert-butyl ester (5) 
 
A solution of DO3A-tBu (4) (1 eq.; 1.5 mmol; 772 mg), N-(2-
propynyl)chloroacetamide (1.2 eq.;  1.8 mmol; 291 mg,) and K2CO3 (2 eq.; 3.0 
mmol; 415 mg) in 70 mL ACN was stirred under nitrogen at reflux temperature 
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for 17 h. After filtration of over Celite®, the solvent was removed in vacuo, the 
residual mixture was purified by basic alumina (eluens CHCl3:MeOH (98:2)) to 
give a colorless solid (yield: 1.45 g, 2.4 mmol, 94%). ESI-MS: m/z calcd 610.80 
[M+H]+, found 632 [M+Na]+. 1H NMR (CDCl3, 300 MHz, δ ppm): 1.45 (s, 18H), 
1.46 (s, 9H), 2.15 (t, J=2.3 Hz, 1H), 2.52 (broad, 4H), 2.70 (broad, 4H), 2.82 
(broad, 4H), 2.91 (broad, 4H), 3.10 (s, 2H), 3.27 (s, 4H), 3.38 (s, 2H), 4.05 (dd, 
J=5.5 Hz, J=2.3 Hz, 2H), 9.27 (t, J=5.5 Hz, 1H); 13C NMR (CDCl3, 75 MHz, δ 
ppm): 28.2, 28.3, 28.6, 29.3, 52.1, 52.5, 53.8, 55.2, 56.2, 57.6, 70.2, 72.9, 80.9, 
170.8. 
Synthesis of {4,10-Bis-carboxymethyl-7-[(2-propynylcarbamoyl)-methyl]-
1,4,7,10-tetraaza-cyclododec-1-yl}-acetic acid (6)  
 
Product (5) (1 eq., 1.45 g, 2.4 mmol) was dissolved in 10 mL of a DCM/TFA 
(50:50) mixture and stirred under inert atmosphere overnight. After the reaction, 
20 mL of DCM was added and evaporated (repeated 2 times) (yield: 1.07 g, 2.4 
mmol, quantitative). ESI-MS: m/z calcd 442.22 [M+H]+, found 442 [M+H]+, 464 
[M+Na]+. 1H NMR (D2O, 300 MHz, δ ppm): 2.42 (t, 1H), 2.48-4.01 (broad, 22H), 
3.81 (broad, 2H); 13C NMR (D2O, 75 MHz, δ ppm): 29.1, 29.6, 49.7, 53.7, 58.6, 
60.6, 60.8, 69.3, 72.7, 73.5, 78.7, 175.4, 179.4, 179.6. 
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General procedure for complexation of propargylated DOTA  
 
General procedure for complexation of propargylated DOTA: Product (6) (1 eq.) 
was dissolved in 5 mL water and the appropriate lanthanide(III) chloride hydrate 
(1.1 eq.) was added. The pH was adjusted to 5.5 with a 0.1 M KOH solution and 
stirred overnight at 60 °C. The solvent was evaporated. The residue was 
redissolved in 5 mL water and Chelex-100 was added and stirred for 2 h. This last 
step was repeated till no free lanthanide was found with an Arsenazo III 
indicator.32  
Propargylated Gd-DOTA (7): (yield: 0.446 g, 0.75 mmol, 67%). ESI-MS: m/z 
calcd 596.70 [M+H]+, found 619.2 [M+Na]+. IR (neat): 𝜈� = 3416, 3245, 3098, 
2873, 1675, 1609 cm–1. 
Propargylated La-DOTA (8): (yield: 0.445 g, 0.77 mmol, 65%). ESI-MS: m/z 
calcd 478.36 [M+H]+, found 600.5 [M+Na]+. 1H NMR (CDCl3, 300 MHz, δ ppm): 
2.42 (t, 1H), 2.48-4.01 (broad, 22H), 3.81 (broad, 2H). 13C NMR (CDCl3, 75 
MHz, δ ppm): 29.1, 29.6, 49.7, 53.7, 58.5, 60.6, 60.8, 69.2, 72.7, 73.5, 78.7, 175.4, 
179.4, 179.6; IR (neat): 𝜈� = 3429, 3258, 3103, 2857, 1673, 1606 cm–1. 
  
| Chapter 5 
 
109 
General procedure flow:  
 
Solution A: a 2 mL solution in a degassed mixture of 10:3:3 MeOH:DCM:H2O of 
1 equivalent BODIPY-amine and 11 equivalents of DIPEA. Solution B: a 2 mL 
solution of 3 equivalents of ISA∙H2SO4 in a degassed mixture of 10:3:3 
MeOH:DCM:H2O. 
Both solutions in a separate syringe are combined via a T-mixer in an ice bath 
before introducing the mixture to the copper tube flow reactor (150 µL) at room 
temperature. Flow speed is adjusted so the retention time in the reactor is 300 
seconds. The column is stabilized during 3 reactor volumes. Upon leaving the 
reactor, the reaction mixture was directly added to a solution of 1.5 equivalents of 
Ln-DOTA-propargyl and 1.5 eq. sodium ascorbate. The mixture is left stirring 
overnight. The aqueous layer is lyophilized, redissolved in distilled water, purified 
via HPLC and lyophilized. The products are isolated as bright orange powders.  
Product (9) (Gd-DOTA-BODIPY): (yield: 13 mg, 0.01 mmol, 6%). ESI-MS: m/z 
calcd 913.85 [M+H]+, found 913.2 [M+H]+. [Gd3+] = 1.454 mmol/l for relaxivity 
study measured by TXRF against a gallium standard. 
Product (10) (La-DOTA-BODIPY): (yield: 23 mg, 0.03 mmol, 9%). ESI-MS: m/z 
calcd 895.51 [M+H]+, found 917.8 [M+Na]+ (positive mode), 894.2 [M+e]- 
(negative mode). 1H NMR (D2O, 300 MHz, δ ppm): 2.08 (s, 6H), 2.20 (s, 6H), 
2.20-3.82 (broad, 26H), 4.33 (broad, H), 6.00 (s, 2H), 7.55 (s, 1H). 11B NMR 
(D2O, 80 MHz, δ ppm): 2.16 ppm with respect to B(OMe)3 as reference. 
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After each reaction the copper tube flow reactor is cleansed in a sonication bath 
for 10 minutes while introducing a 1:1 mixture of MeOH:triethylamine at 4 
mL/min, followed by 20 mL of pentane at 4 mL/min. The reactor is dried with 
argon and stored under argon.  
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CHAPTER 6 
Towards T1 contrast agents  
via copper mediated 
cycloaddition 
 
 
Ligand design, synthesis and characterization of the luminescent complexes were 
done by Drs. Matthias Ceulemans. Gratitude goes towards Prof. Koen Binnemans 
for TXRF measurements. 
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1 Introduction 
Magnetic resonance imaging (MRI) as a diagnostic tool has grown over the past 
years.1–6 Gadolinium(III) chelates have some interesting properties that efficiently 
induce relaxation of water molecules.1 In modern molecular imaging techniques 
the commonly used contrast agents are the acyclic diethylenetriaminepentaacetic 
acid (Gd-DTPA) and the cyclic 1,4,7,10-tetraazacyclododecane-1,4,7,10-
tetraacetic acid (Gd-DOTA).2 The eight-fold coordination ensures stability (log K 
= 22.5 and 25.3 for Gd-DTPA and Gd-DOTA respectively), and allows the 
binding of one water molecule directly to the metal center.7–9 MRI suffers from a 
low sensitivity; on the contrary, optical imaging (OI) is a very sensitive technique. 
Combination of both MRI and OI into one probe would allow images to reveal 
more details, ensure the same biodistribution and reduce the stress imposed on the 
body than using two separate probes. For the design of in vivo probes tissue 
penetration is a very important factor when deciding which fluorophores to use. A 
good trade-off between the image resolution and penetration depth can be made in 
the region between 665 to 900 nm.10 BODIPY dyes are a class of small organic 
molecules with very high extinction coefficients, fairly sharp fluorescence peaks 
and high quantum yields. Their emission wavelength is tunable by increasing the 
resonance within the BODIPY core.11 
Although BODIPY dyes were known since the late 1960s, it was only in the 1990s 
that the true versatility of these dyes were fully recognized.12 The first publication 
reporting on successful linkage of a DOTA moiety with a BODIPY derivative was 
published by Bernhard et al.13 The goal is to develop a potential bimodal imaging 
agent for optical and nuclear imaging (PET/CT). So far no reports of the use of 
BODIPY-DOTA derivatives used for optical and magnetic resonance imaging are 
known. In this chapter different synthetic procedures are highlighted in order to 
couple DOTA to BODIPY dyes. The general ligand design consists of suitable 
BODIPY dyes preparation in order to covalently bind them to a DOTA moiety by 
a modular approach. 
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2  Results and discussion 
2.1 Ligand design and synthesis 
The first approach to obtain an optical and MRI probe uses the coupling between 
free acid and free amine group to form a stable amide bond. In a second approach 
a copper mediated cycloadditon was used in order to synthesize a BODIPY 
derivative with a La-DOTA complex.  
2.1.1 DOTA-BODIPY via coupling reagents 
 
Ligand design and synthesis 
 
In the first approach we attempted to synthesize the potential bimodal contrast via 
coupling using peptide synthesis (Scheme 6.1). With this approach a carboxylic 
acid and an amine can be coupled with coupling agents such as TBTU or HATU. 
We opted for the approach in which an acid group on DOTA would be coupled to 
an amine on BODIPY, due to available expertise within the group.   
 
Scheme 6.1. The structure of the final targeted potential bimodal MRI contrast agent. 
The synthetic strategy behind a single acid group containing DOTA ligand is 
straightforward. Three amine functionalities of cyclen are selectively substituted 
with tert-butyl bromoacetic acid as shown in Scheme 6.2. To ensure formation of 
DO3A-tBu, 3.5 equivalents of tert-butyl bromoacetate were used. A purification 
step is required to separate the desired product DO3A-tBu from the undesired 
byproduct DOTA-tBu. At first, column chromatography with basic alumina was 
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used, but separation of the two products was not satisfactory and impure, off-white 
solids were obtained. Simple crystallization from toluene lead to pure DO3A-tBu 
as a white solid. The fourth amine of DO3A-tBu was substituted with benzyl 
bromoacetate and subsequent hydrogenation over Pd/C and hydrogen gas, either 
via a Parr shaker or under atmospheric pressure, lead to a free carboxylic acid 
derivative in high yields. 
  
Scheme 6.2. Synthetic pathway for a free acid containing DOTA derivative. : a) 3.5 eq. 
tert-butyl bromoacetate, NaHCO3, ACN, reflux, overnight; b) benzyl bromoacetate, 
K2CO3, ACN, reflux, overnight; c) Pd/C (5%), H2, 4 h, Parr shaker; d) amide 
formation. 
The meso position of the BODIPY core was used to bear an amine function, 
because this position makes it easy to prepare desired derivatives with readily 
available starting materials. In a first approach, benzyl carbamate (Cbz) protected 
amine was used to build up the BODIPY core, because these groups are easily 
removed via hydrogenation and should protect the amine from nucleophilic 
attacks. During acyl chloride formation, only a five membered ring is observed 
when 5-(carbobenzoxyamino)valeric acid was used (Scheme 6.3).  
| Chapter 6 
 
117 
 
Scheme 6.3. Synthetic strategy to form a Cbz-protected BODIPY. 
Only a six membered ring is formed. 
In a second approach an aniline group is introduced on the meso position of the 
BODIPY core. The synthetic procedure starts from 4-nitrobenzoic acid or 4-
nitrobenzaldehyde. Conversion of 4-nitrobenzoic acid into an acyl chloride with 
thionyl chloride and subsequent reaction with two equivalents of 2,4-
dimethylpyrrole forms a meso nitrophenyl-dipyrromethene. The same product is 
formed in a one-pot synthesis by reacting 4-nitrobenzaldehyde with two 
equivalents of 2,4-dimethylpyrrole in the presence of an acid catalyst, followed by 
reaction by a mild oxidant such as p-chloranil. The meso nitrophenyl-
dipyrromethene is subsequently complexed with boron trifluoride diethyl etherate 
(BF3·Et2O) and a triethylamine as base to form the bright green emissive BODIPY 
8-nitrophenyl derivative (Scheme 6.4). 
 
Scheme 6.4. Two synthetic pathways to form meso nitrophenyl-
dipyrromethene. Complexation with boron trifluoride diethyl 
etherate and a base leads to the bright green emissive BODIPY 8-
nitrophenyl. 
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Two methods are explored to reduce the nitro function to an amine: Pd/C 
catalyzed hydrogenation with H2 or reduction with hydrazine. The first method 
has been proven to be much slower than the second. Boiling BODIPY 8-
nitrophenyl, hydrazine, and a catalytic amount of palladium (5%) on carbon in 
ethanol for two hours and filtration leads to the desired product in good yields 
(Scheme 6.5). 
 
Scheme 6.5. Synthesis of BODIPY 8-aminophenyl: 5 eq. H4N2, cat. Pd 
(5%)/C, EtOH, reflux, 2 h. 
The aniline of BODIPY 8-aminophenyl was used in a coupling reaction with the 
free acid containing DOTA derivative. To facilitate the reaction by activating the 
carboxylic acid group, several coupling reagents were used: 1-
[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxid-
hexafluorophosphate (HATU) and dicyclohexylcarbodiimide (DCC) with N-
hydroxysuccinimide (NHS). Unfortunately all the coupling reactions resulted in 
impure samples that were collected after alumina column purification. 
 
Scheme 6.6. BODIPY 8-aminophenyl in a coupling reaction with the free acid 
containing DOTA derivative using coupling reagents forming the desired fully 
protected BODIPY derivative. 
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To achieve the better separation of the byproducts another approach was 
attempted. In this method the BODIPY 8-aminophenyl was alkylated with 
bromoacetyl bromide prior to a substitution reaction with the amine of DO3A-tBu. 
The nucleophilic substitution was done as a first attempt under reflux conditions in 
DMF with K2CO3 as a base. Destruction of the BODIPY complex was observed 
after this overnight reaction. In a second approach lower temperatures were used 
to complete the reaction. Strong bases such as sodium hydride at 0 °C can be used 
to deprotonate the amine leading to a very reactive nucleophile. An easy 
extraction step resulted in the desired product which was characterized by means 
of ESI-MS and NMR.  
 
Scheme 6.7. Acylation with subsequent nucleophilic substitution 
yields a protected BODIPY derivative. A) DO3A-tBu, NaH, 0 °C. 
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The 1H NMR spectrum of the acylated  BODIPY 8-aminophenyl shows the amide 
proton at 8.20 ppm, two doublets (J = 8 Hz) at 7.20 and 7.64 ppm, assigned to the 
aromatic protons, a distinct peak of the BODIPY core at 5.94 ppm and the methyl 
protons at 2.54 and 1.39 ppm. The singlet at 3.99 ppm is assigned to the protons 
next to the bromine (Figure 6.1).  
 
Figure 6.1. 1H NMR spectrum of the acylated BODIPY 8-aminophenyl. 
In the final product the large peak at 1.44 ppm is assigned to the t-Bu groups and 
the observed broad bands between 2.58–3.42 ppm to the ring protons of the 
DOTA moiety.14 The BODIPY peaks are found in the final product and are 
shifted: the two aromatic doublets (J = 8 Hz) at 7.14 and 8.02 ppm, two protons of 
the BODIPY core at 5.94 ppm and the methyl protons at 2.54 and 1.39 ppm. The 
singlet at 3.99 ppm is shifted towards lower values (Figure 6.2). Deprotection and 
subsequent complexation were further performed in order to obtain the final 
desired potential bimodal probe, however the BODIPY derivative was destroyed 
during the deprotection step. 
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Figure 6.2. 1H NMR spectrum of the BODIPY derivative. 
 
2.1.2 DOTA-BODIPY via copper mediated cycloaddition 
Ligand design and synthesis 
The second approach used copper mediated cycloaddition which led to the 
formation of azide containing BODIPYs. Commercially available BODIPY 
derivatives BODIPY 8-chloromethane and BODIPY 8-bromomethane were first 
considered for this approach. As prices for these dyes are considerably large (1120 
USD/100 mg)15 the option to synthesize these derivatives from the readily 
available and cheap bromoacetyl bromide or chloroacetyl chloride was chosen. 
The final products can be made in a simple one-pot two-step reaction (Scheme 8). 
Attempts were made to substitute the halogen with sodium azide, but no 
substitution was found. Also in literature no examples are found of this type of 
reaction. 
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Scheme 6.8. The synthetic pathway of BODIPY 8-chloromethane and 
BODIPY 8-bromomethane. A simple two step reaction leads to the 
desired products. 
In a second approach two BODIPY azides were reproduced from known reaction 
pathways from literature and are depicted in figure 6.3.16,17 The BODIPY-Ph-N3 is 
synthesized from the BODIPY 8-aminophenyl derivative, where via a diazonium 
compound the azide was substituted in a one pot synthesis. BODIPY-(CH2)3-N3 
was obtained via a substitution reaction of BODIPY-(CH2)3-Cl which was 
obtained by using 4-chlorobutyryl chloride and 2 equivalents of 2,4-
dimethylpyrrole followed by complexation with BF3·Et2O and a base. These azide 
containing BODIPY derivates are used in copper mediated cycloaddition with the 
propargylated DOTA complex, as discussed in previous chapter (Figure 4). The 
DOTA moiety should be chelated with a lanthanide ion prior the copper mediated 
cycloaddition, as the copper catalyst used will form strong complexes with the 
DOTA derivative.   
 
Figure 6.3. BODIPY azide derivatives from literature used in the 
copper mediated cycloaddition. 
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In the copper mediated cycloaddition the azides were mixed with the 
propargylated La-DOTA complex in combination with copper sulphate and 
sodium ascorbate, which will generate the active Cu(I) species. The desired 
products were collected after an HPLC purification and analyzed using NMR in 
solution. 
 
Figure 6.4. Structure of the propargylated Ln-DOTA (Ln = La(III)) derivative. 
 
Figure 6.5. Molecular structures of the synthesized La-DOTA-BDP4 (left) and La-
DOTA-BDP5 (right) via a copper mediated cycloaddition. 
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No clear NMR data could be recorded for La-DOTA-BDP4, but the HPLC trace 
of the purified product suggests the formation of the final product with a 
molecular mass of 941.2 g/mol (see Experimental section). 
The 1H NMR spectrum of La-DOTA-BDP5 shows a distinct peak of the triazole 
proton at 7.77 ppm and two protons on the BODIPY core at 5.99 ppm, indicating a 
successful linkage of the DOTA moiety with the BODIPY derivative. The 1H 
NMR spectrum also shows broad peaks in the region from 2.20-3.82 ppm which 
are typical for the protons in the DOTA ring.14 The formation of the final product 
can also be seen in the HPLC trace (see Experimental section). 
 
Figure 6.6. 1H NMR spectrum of La-DOTA-BDP5 measured in D2O. 
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Photophysical properties 
The final BODIPY derivatives are water soluble due to the linkage of the polar 
La-DOTA complex. The electronic absorption spectra shown in figure 6.7 depict 
characteristic and rather narrow absorption bands typical for BODIPY dyes. Both 
absorption patterns are similar which would be expected for the same BODIPY 
core. The main absorption band with a maximum λabs(max) at 496 and 499 nm are 
observed in aqueous solution for La-DOTA-BDP4 and La-DOTA-BDP5 
respectively. An additional, considerably weaker broad absorption band is 
observed in the UV-Vis region around 350 nm. The solutions emit a green 
fluorescence upon excitation. A shift in the optical properties of the BODIPY dyes 
can easily be tuned by increasing conjugation by placing different substituents on 
the BODIPY core. The BODIPY core is very apolar and dissolves well in apolar 
organic solvents. When altering the BODIPY core, water solubility must be taken 
into account. 
 
Figure 6.7. The absorption spectra of La-DOTA-BDP4 (full  line)  
and La-DOTA-BDP5 (dashed line).  
The emission maxima of La-DOTA-BDP4 and La-DOTA-BDP5 are observed at 
508 and 510 nm respectively (Figure 6.8). The excitation maximum, measured at 
an emission wavelength of 525 nm, shows a maximum at 497 nm and has a 
similar shape to the absorption maximum.  
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The fluorescent quantum yields of La-DOTA-BDP4 and La-DOTA-BDP5 were 
determined upon ligand excitation (490 nm) by a comparative method, using a 
solution of Rhodamine 6G (Q = 78%)18 in water as the standard. QY values of 
39% and 64% were recorded respectively. The QY of La-DOTA-BDP4 is lower 
than expected. Energy transfer towards the phenyl ring from the BODIPY core 
could be an explanation. No relaxometric data was obtained as no gadolinium(III) 
derivatives were synthesized. The relaxivity of both complexes could be assumed 
to be in the range of previously reported values for Gd-DOTA complexes, which 
is 3.5 and 3.1 s-1mM-1 at 20 and 60 MHz respectively.19  
 
Figure 6.8. Emission (black, λex = 490 nm) and excitation (grey, λem 
= 525 nm) spectrum of La-DOTA-BDP4 (solid line) and La-
DOTA-BDP5 (dashed line). 
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3 Conclusions 
In this chapter an attempt to synthesize a novel Gd-DOTA-BODIPY derivative 
was described. Unfortunately, the final product could not be obtained as the 
BODIPY core was destroyed during the deprotection in a final step. The synthesis 
and characterization of two novel BODIPY derivatives, La-DOTA-BDP4 and La-
DOTA-BDP5, is also highlighted in this chapter. The complexes are water-soluble 
and exhibit good fluorescent properties. Upon ligand excitation in water a bright 
emission was observed at 508 and 510 nm with an observed quantum yield of 39% 
and 64% for La-DOTA-BDP4 and La-DOTA-BDP5 respectively. In the future an 
emission shift to the more optimal red-IR region of the spectrum can be attempted 
by increasing the electronic resonance of the BODIPY by adding appropriate 
substituents to the BODIPY core. Gadolinium(III) containing derivatives should 
be synthesized to measure the relaxometric properties. Due to the similar size, it is 
expected that the relaxivity of these compounds will be in the range of previously 
reported values for Gd-DOTA complexes.  
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4 Experimental section 
Synthesis of DO3A-tBu (1) 
The synthesis was written in a previous chapter. 
Synthesis of tri-tert-butyl 2,2',2''-(10-(2-(benzyloxy)-2-oxoethyl)-1,4,7,10-
tetraazacyclododecane-1,4,7-triyl)triacetate (2) 
 
To a suspension of DO3A-tBu (1) (1 eq.; 1.0 mmol; 0.535 g) and K2CO3 (3 eq.; 
3.0 mmol; 0.431 g) in 100 mL acetonitrile was a 50 mL solution dropwise added 
of benzyl bromoacetate (1.1 eq.; 1.1 mmol; 0.262 g) in ACN. The resulting 
suspension was refluxed overnight after which the salts were removed via 
filtration over Celite® and the solvent was concentrated in vacuo. The oily residue 
was further purified via column chromatography, basic alumina (eluent: 
DCM:MeOH 98:2), to a colorless oil (yield: 0.398, 60%). ESI-MS: m/z calcd: 
663.86 g/mol [M+H]+, found: 686 g/mol [M+Na]+. 1H NMR (CDCl3, 300 MHz, δ 
ppm): 1.45 (s, 27H), 2.82 (m, 16H), 3.29 (m, 6H), 3.47 (s, 2H), 5.15 (s, 2H), 7.33 
(m, 5H); 13C NMR (CDCl3, 75 MHz, δ ppm): 27.9, 27.9, 28.0, 55.0, 55.2, 55.6, 
55.8, 66.9, 67.0, 81.9, 128.4, 128.6, 128.7, 135.1, 173.0, 173.1, 173.6, 173.7.  
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Synthesis of 2-(4,7,10-tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-
tetraazacyclododecan-1-yl)acetic acid (3) 
 
Product (2) (1 eq.; 0.53 mmol; 0.350 g) was dissolved in 10 mL MeOH and 10 
mol% of palladium (5%) on carbon was added. The suspension was put under 
hydrogen atmosphere in a Parr shaker for 4 hours. The catalyst was filtered off 
with a Millipore FH 0.45 µm filter and concentrated and a colorless oil was 
obtained. (yield: 0.296 g, quantitative). ESI-MS (MeOH, m/z): calcd: 573.73 
g/mol [M+H]+, found: 596 g/mol [M+Na]+. 1H NMR (CDCl3, 300 MHz, δ ppm): 
1.46 (s, 27H), 1.9-3.58 (very broad, 24H); 13C NMR (CDCl3, 75 MHz, δ ppm): 
27.9, 28.1, 55.5, 55.9, 56.1, 82.2, 172.4, 174.7.  
Synthesis of BODIPY 8-nitrophenyl (4) 
 
To a solution of 4-nitrobenzaldehyde (1 eq.; 5.0 mmol; 0.756 mg) in 25 mL of 
DCM was added 2,4-dimethylpyrrole (2 eq.; 10 mmol; 1.04 mL) and two drops of 
trifluoroacetic acid. The solution was stirred for 1 h and p-chloranil (1 eq.; 5 
mmol; 1.23 g) was added. The mixture was allowed to stir for an additional 2 
hours. The solution was then cooled to 0 °C and triethylamine (10 eq.; 50 mmol; 
6.94 mL) was added. After 5 minutes of stirring at 0 °C boron trifluoride diethyl 
etherate (11 eq.; 55 mmol; 7.56 mL) was slowly added and the solution was stirred 
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at room temperature overnight. The solution was diluted with diethyl ether (200 
mL) and the organic layer was washed with water (3x 75 mL). The organic layer 
was dried with MgSO4 and concentrated in vacuo. The resulting residue was 
purified using silica column (eluent: DCM/PET 1:1) yielding a red solid (yield: 
0.320 g, 17%). 1H NMR (300 MHz, CDCl3, δ ppm): 1.36 (s, 6H), 2.56 (s, 2H), 
6.02 (s, 2H), 7.52 (d, J=8.7 Hz, 2H), 8.37 (d, J=8.7 Hz, 2H); 13C NMR (75 MHz, 
CDCl3, δ ppm): 14.7, 121.9, 124.4, 129.7, 130.6, 138.4, 141.9, 142.5, 148.4, 
156.7. 
Synthesis of BODIPY 8-aminophenyl (5) 
 
To a solution of BODIPY-Ph-NO2 (1 eq.; 0.87 mmol; 0.320 g) in 35 mL ethanol 
was added 10 mg of palladium (5%) on carbon and hydrazine hydrate (5 eq.; 4.30 
mmol; 0.210 mL). The mixture was refluxed for 2 h under inert atmosphere. The 
mixture was allowed to cool and the solids were filterd over a Millipore 0.45 µm 
filter. The organic layer was concentrated in vacuo yielding an orange solid (yield: 
0.295 g, quantitative). ESI-MS (MeOH, m/z): calcd: 339.19 g/mol [M+H]+, found: 
1040.7 g/mol [3M+Na]+.  1H NMR (300 MHz, CDCl3, δ ppm): 1.49 (s, 6H), 2.55 
(s, 2H), 3.84 (broad, 2H), 5.97 (s, 2H), 6.76 (d, J=8.5 Hz, 2H), 7.26 (d, J=8.5 Hz, 
2H); 13C NMR (75 MHz, CDCl3, δ ppm): 14.5, 14.6, 115.4, 120.9, 124.6, 128.9, 
132.0, 142.7, 143.2, 147.1, 155.0. 
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Synthesis of BODIPY-Ph-NH-Acyl (6) 
 
BODIPY-Ph-NH2 (5) (1 eq.; 0.15 mmol; 50 mg) and triethylamine (1.5 eq.; 0.22 
mmol, 22.8 mg) were dissolved in 20 mL dry DCM and cooled to 0 °C. 
Bromoacetyl bromide (1 eq.; 0.15 mmol; 30.3 mg) was added dropwise and the 
reaction was allowed to stir at 0 °C for 30 minutes and subsequently slowly heated 
to room temperature and left stirring overnight. The solution was washed with 2 M 
HCl (20 mL) and water (2x 20 mL). The organic layer was dried and evaporated 
till a dark red solid (yield: 0.049 g, 71%). EI-MS: calcd: 461.12 g/mol [M+H]+, 
found: 459 g/mol [M-H]+. 1H NMR (300 MHz, CDCl3, δ ppm): 1.35 (s, 6H), 2.48 
(s, 4H), 3.99 (s, 2H), 5.91 (s, 2H), 7.20 (d, J=8.7 Hz, 2H), 7.63 (d, J=8.7 Hz, 2H), 
8.20 (s, 1H); 13C NMR (75 MHz, CDCl3, δ ppm): 14.5, 16.6, 26.0, 119.0, 121.9, 
124.0, 124.5, 131.5, 140.3, 147.1, 147.6, 154.4, 167.0. 
Synthesis of BODIPY 8-chloromethane (7) 
 
To a solution of 2,4-dimethylpyrrole (2 eq.; 4.86 mmol; 0.462 g) in 25 mL dry 
DCM was chloroacetyl chloride (1 eq.; 2.43 mmol; 0.193 mL) added dropwise at 
0 °C. The solution was allowed to stir for 30 minutes at 0 °C and was then 
refluxed for 3 h. The solution was subsequently cooled to 0 °C and 40 mL of 
DCM was added. Triethylamine (10 eq.; 25.3 mmol; 3.53 mL) was added to the 
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solution. After 5 minutes of stirring at 0 °C, boron trifluoride diethyl etherate (11 
eq.; 26.73 mmol; 3.30 mL) was slowly added and the solution was stirred at room 
temperature overnight. Diethyl ether (100 mL) was added to the solution and the 
organic layer was washed with water (3x 50 mL). The organic layer was dried 
with MgSO4 and concentrated in vacuo. The resulting residue was purified using 
silica column (eluent: DCM/PET 1:1) yielding a red solid (yield: 0.441 g, 30%). 
CI-MS (MeOH, m/z): calcd: 297.55 g/mol [M+H]+, found: 262 g/mol [M-Cl]+. 1H 
NMR (300 MHz, CDCl3, δ ppm): 2.53 (s, 12H), 4.77 (s, 2H), 6.09 (s, 2H); 13C 
NMR (75 MHz, CDCl3, δ ppm): 14.7, 15.5, 37.1, 121.3, 131.4, 135.9, 141.1, 
156.6. 
Synthesis of BODIPY 8-bromomethane (8) 
 
The synthesis is analogous to the synthesis of BODIPY 8-chloromethane. Yield a 
dark red solid (yield: 0.148 g, 9%). CI-MS (MeOH, m/z): calcd: 342.00 g/mol 
[M+H]+, found: 261 g/mol [M-Br]+. 1H NMR (300 MHz, CDCl3, δ ppm): 2.54 (s, 
6H), 2.55 (s, 6H), 4.68 (s, 2H), 6.09 (s, 2H); 13C NMR (75 MHz, CDCl3, δ ppm): 
14.7, 15.9, 24.5, 121.3, 131.0, 137.3, 140.9, 156.4. 
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Synthesis of BODIPY-Ph-N3 (9) 
 
BODIPY-Ph-NH2 (5) (1 eq.; 0.84 mmol; 0.285 g) was dissolved in 15 mL of 1.0 
M HCl/MeOH, cooled to 0 °C and stirred for 10 minutes. NaNO2 (2.5 eq.; 2.1 
mmol; 0.145 mg) in 1.0 mL of water, was added over 5 minutes and the solution 
was stirred for 1 h at 0 °C. NaN3 (5 eq.; 4.2 mmol; 0.273 g) was added and stirred 
for an additional hour at room temperature. The solvents were evaporated and the 
residue was redissolved in 25 mL ethyl acetate. The organic layer was washed 
with water (2x 20 mL) and brine (20 mL). The organic layer was and dried over 
MgSO4 and evaporated. The product was purified via column chromatography 
(Heptane:EtOAc 7:3) as an orange solid (yield: 0.151 g, 49%). 1H NMR (300 
MHz, CDCl3, δ ppm): 1.41 (s, 6H), 2.54 (s, 6H), 5.98 (s, 2H), 7.13 (d, J=8.36 Hz, 
2H), 7.26 (d, J=8.36 Hz, 2H); 13C NMR (75 MHz, CDCl3, δ ppm): 14.6, 119.8, 
121.4, 129.7, 131.6, 140.6, 141.1, 145.9, 155.8. 
Synthesis of BODIPY-(CH2)3-Cl (10) 
 
To a solution of 4-chlorobutyryl chloride (1 eq.; 5.0 mmol; 0.56 mL) in 25 mL dry 
DCM was added 2,4-dimethylpyrrole (2 eq.; 10 mmol; 1.04 mL). The solution 
was allowed to stir for 30 minutes at room temperature while the solution turned 
dark red. The solution was subsequently refluxed for 4 h. The solution was then 
cooled to 0 °C and triethylamine (10 eq.; 50 mmol; 6.94 mL) was added. After 5 
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minutes of stirring at 0 °C boron trifluoride diethyl etherate (11 eq.; 55 mmol; 
7.56 mL) was slowly added and the solution was stirred at room temperature 
overnight. Diethyl ether (200 mL) was added to the solution and the organic layer 
was washed with water (3x 75 mL). The organic layer was dried with MgSO4 and 
concentrated in vacuo. The resulting residue was purified using silica column 
(eluent: DCM/PET 1:1) yielding a red solid (yield: 0.345 g, 21%). ESI-MS 
(MeOH, m/z): calcd: 325.60 g/mol [M+H]+, found: 349.8 g/mol [M+Na]+. 1H 
NMR (300 MHz, CDCl3, δ ppm): 2.05 (m, 2H), 2.41 (s, 6H), 2.51 (s, 6H), 3.10 
(m, 2H), 3.68 (t, 2H), 6.05 (s, 2H); 13C NMR (75 MHz, CDCl3, δ ppm): 14.5, 16.5, 
25.9, 34.0, 44.7, 121.9, 131.4, 140.4, 144.4, 154.3. 
Synthesis of BODIPY-(CH2)3-N3 (11)  
 
To a solution of BODIPY-(CH2)3-Cl (10) (1 eq.; 1.76 mmol; 0.570 g) in DMF (36 
mL) was sodium azide (2 eq.; 3.51 mmol; 0.228 g) added and stirred for 36 h at 40 
°C. The reaction was cooled to room temperature and 30 mL of water was added. 
The mixture was extracted with ethyl acetate (3x 20 mL), the organic layer was 
washed with water (20 mL), brine (20 mL) and dried with MgSO4. The solvent 
was evaporated in vacuo and the resulting residu was purified via column 
chromatography (Heptane:EtOAc 7:3) as an orange solid (yield: 0.345 g, 59%). IR 
(neat): ν� = 2102 cm-1 (azide). 1H NMR (300 MHz, CDCl3, δ ppm): 1.87 (m, 2H), 
2.43 (s, 6H), 2.52 (s, 6H), 3.04 (m, 2H), 3.49 (t, 2H), 6.06 (s, 2H); 13C NMR (75 
MHz, CDCl3, δ ppm): 14.5, 16.4, 25.6, 31.1, 51.5, 121.9, 131.4, 140.3, 144.6, 
154.3. 
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Synthesis of La-DOTA-BDP4 (12)  
 
BODIPY-Ph-N3 (9) (1 eq.; 0.03 mmol; 10 mg) and propargylated La-DOTA (1 
eq.; 0.03 mmol; 16 mg) were dissolved in 3 mL of a 10:3:3 MeOH/DCM/H2O 
mixture. Cu(II)SO4 (10 mol%) and sodium ascorbate (20 mol%) were added as 0.1 
M solutions in water. Three drops of triethylamine are added and the solutions are 
stirred for 24 h in the dark. The solvents were evaporated and the compound is 
purified via HPLC. ESI-MS (MeOH, m/z): calcd: 941.55 g/mol [M-H]-, found: 
941.2 g/mol [M-H]-. Yield: 2 mg, 5%. 
 
Synthesis of La-DOTA-BDP5 (13)  
 
BODIPY-(CH2)3-Cl (10) (1 eq.; 0.1 mmol; 33 mg) and propargylated La-DOTA 
(1 eq.; 0.1 mmol; 58 mg) was dissolved in 6 mL of a 10:3:3 MeOH/DCM/H2O 
mixture. Cu(II)SO4 (10 mol%) and sodium ascorbate (20 mol%) were added as 0.1 
M solutions in water. Three drops of triethylamine are added and the solutions are 
stirred for 24 h in the dark. The solvents were evaporated and the compound is 
purified via HPLC. ESI-MS (MeOH, m/z): calcd: 909.53 g/mol [M+H]+, found: 
909.3 g/mol [M+H]+. Yield: 5 mg, 6%. 
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NMR: 1H NMR (300 MHz, CDCl3, δ ppm): 0.98-3.81 (broad, 40H); 4.31 (broad, 
4H), 5.99 (s, 2H), 7.77 (s, 1H). 
HPLC trace La-DOTA-BDP4: 
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HPLC trace La-DOTA-BDP5: 
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GENERAL CONCLUSIONS  
&  
FUTURE OUTLOOK 
Four different potential bimodal contrast agents for optical and magnetic 
resonance imaging have been synthesized and thoroughly investigated. All are 
different in their design, synthetic approach, and properties. 
The first approach is based on metallostar complexes based on dipicolinic acid 
(DPA) and diethylene triamine pentaacetic acid (DTPA) to produce potential T1 
contrast agents. In these bitopic ligands, two different lanthanides are 
incorporated. The Gd-DTPA is coupled via an amide bond to the DPA moiety, 
which self-assembles around a luminescent lanthanide. The three types of 
metallostars differ by the linkage of the phenyl group of the DPA moiety. The 
luminescent properties of the complexes diverge strongly over the different 
ligands. For europium(III), terbium(III) and dysprosium(III) characteristic 
emission could be recorded, but the quantum yield changed greatly depending on 
the ligand. For example, GdL1 showed much better luminescent quantum yields 
for all studied complexes, while GdL2 was able to sensitize ytterbium(III) in solid 
state samples. The NMRD measurements of the complexes showed an increase in 
longitudinal relaxivity values r1 in comparison to Gd-DTPA. For example the 
(GdL2)3Ln complexes (Ln = Eu(III), Dy(III), Tb(III)) showed values of 24.27, 
22.80 and 21.72 s-1mM-1 respectively per metallostar complex at 310 K and 20 
MHz.  
 
In a second approach small monodisperse multimodal iron oxide nanoparticles 
were functionalized with three novel boron-dipyrromethene (BODIPY) 
derivatives as potential T2/T2* contrast agents. The dyes are covalently attached 
onto the nanoparticles surface via thiolene click chemistry, after which bright 
fluorescence is observed for these nanoparticles. Relaxivity studies on agar 
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phantoms showed an r2 value of 49 ± 3 and 47 ± 7 s-1mM-1 for NP-BDP1 and NP-
BDP3 respectively. Cell viability studies showed no significant cytotoxicity at any 
of the tested concentrations on rat tumor (AR42J) and human ovarian cancer 
(SKOV3) cells. Human hepatic stellate (GRX) cells were only significantly 
affected by the NPs at the highest concentrations. 
 
In a third approach another type of potential T1 contrast agents are developed and 
investigated. The synthetic approach uses azide diazotransfer chemistry in a 
copper tube flow reactor, where the formed azide is coupled directly with a Gd-
DOTA moiety via copper mediated cycloaddition forming a novel Gd-DOTA 
complex functionalized with a BODIPY dye. The paramagnetic gadolinium(III) 
chelate will act as a T1 contrast agent. This BODIPY dye is a small organic 
molecule which functions as the optical probe and emits at 523 nm with a high 
quantum yield. The emission wavelength of the dye should be adjusted by altering 
the resonance structure of the core so it falls within the optical window. The 
proton relaxivity of the complex shows a potential use as a bimodal contrast agent 
for optical and MRI. A lanthanide(III) analogue has been synthesized and the 
NMR spectrum is fully analyzed. 
 
At first peptide chemistry was used in a fourth approach to synthesize a novel 
protected DOTA-BODIPY derivative. Unfortunately, the BODIPY core was 
destroyed during deprotection and a final complex could not be obtained. Azide 
containing BODIPY derivatives are reproduced from literature and are combined 
with lanthanum(III)-DOTA chelates via a copper mediated cycloaddition reaction. 
The resulting complexes are water-soluble and exhibit good fluorescent properties. 
Fairly high quantum yields of 39% and 64% are obtained for La-DOTA-BDP4 
and La-DOTA-BDP5 respectively. The emission wavelength of the dye should be 
adjusted so it falls within the optical window. Gadolinium(III) containing 
derivatives should also be synthesized to measure the relaxometric properties. Due 
to the similar size and internal rotation, it is expected that the relaxivity of these 
compounds will be in the range of previously reported values for Gd(III)-DOTA 
complexes. 
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As a general conclusion, the above described chemical compounds exhibited 
favorable physicochemical properties to act as potential multimodal contrast 
agents for optical and magnetic resonance imaging. The rotational correlation time 
has effectively been increased because of the rigid structure and high molecular 
mass, thus the metallostar complexes gave the best longitudinal relaxivity (r1). 
The optical results are promising, as the emission wavelength of terbium(III) and 
europium(III) are close to the optical window, but suffer from relatively low 
quantum yields. The opposite is true for compounds containing BODIPY dyes. 
Very high fluorescent quantum yields can be obtained, but modest values of r1 
which are comparable to clinically used contrast agents, have been obtained.  
 
These designed structures have interesting characteristics and should be tested in 
cells and/or mice for biocompatibility studies. To circumvent the equilibrium 
between the bis and tris form of the metallostar complexes, the dipicolinate 
moieties could be joined together in a macrocyclic ring. The stability constant and 
the quantum yield of the central ion will be higher. Other chelating derivatives, 
such as coumarin, could be considered to form metallostar complexes. Coumarin 
derivatives generally absorb at higher wavelengths which would be better for in 
vivo use. 
 
The iron oxide nanoparticles show good transverse relaxivity and optical 
properties. Both IO-BDP1 and IO-BDP2 discussed in chapter 4 will have a 
minimal use in medical imaging as the emission wavelength is to low or the 
particles are not water dispersible. IO-BDP2 shows to be potentially useful for 
applications such as in polymer blends or thin film production. IO-BDP3 would be 
a valuable candidate for medical imaging use, as the emission wavelength is in the 
optical window and exhibits low cellular toxicity. Further studies could involve in 
vivo experiments to study the biocompatibility. Increasing the stability in solution 
of nanoparticles by adding longer ethylene glycol chains could be considered. 
Another interesting approach is the development of bimodal targeted contrast 
agents by introducing RGD mimetic, folic acid or antibodies to the surface of the 
nanoparticles. Possible photodynamic therapy could be obtained by an addition of 
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iodine containing BODIPY derivatives to the surface of the iron oxide 
nanoparticle. Or a mixture of different emissive BODIPY dyes can also be grafted 
to the surface which would lead to a MRI and a dual optical imaging probe. 
The relaxivity of the Gd-DOTA containing BODIPY dyes should be improved. In 
a first approach a rigid system should be made to limit the internal motion of the 
Gd-DOTA moiety. In a second approach to decrease the rotational correlation 
time, interactions with macromolecules such as human serum albumin can be 
considered. In previous studies it was shown that a small apolar group can 
reversible interact with proteins in the bloodstream, increasing the relaxivity of the 
complex. RGD mimetic molecules can be incorporated to selectively target cells 
and increase the relaxivity. Multi-component reactions, such as the Ugi reaction, 
could be considered to easily prepare such complex structures. 
 
The development of new bimodal contrast agents was always considered for the 
reported compounds, but they could also be a platform for other scientists from 
different fields such as, biology, engineering, and medicine, in their search for 
new applications. 
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SAFETY ASPECTS 
All lab experiments were performed in compliance with the Code of practice for 
Safety in the Lab (KU Leuven) and the Introductory Safety Brochure (Department 
of Chemistry). Risk assessments were drafted for all experiments. The approved 
risk assessments are stored on the departmental Risk assessment website. All lab 
experiments were conducted using the appropriate safety measures such as: lab 
coat, safety glasses and gloves.  
Extra care was taken when working with E4 products such as diethyl ether, 
dimethylformamide, and methanol or potential carcinogenic materials. Azides are 
a highly reactive commonly used in both chemical synthesis and biomedical 
research applications. Azides (inorganic and organic) possess toxic properties and 
can be potentially explosive and shock sensitive under certain conditions. 
Therefore, azides require precaution during preparation, storage, handling and 
disposal. Never add NaN3 to acidic wastes or small halogenated molecules, as this 
can produce highly toxic and explosive products. Waste collection was done in the 
provided waste containers. Since the effects of nanoparticles with the human skin 
or internal metabolism are not completely understood, extra care was taken when 
manipulating these products. Waste was collected separately in plastic bags before 
general disposal. Nanoparticles were always stored as colloidal suspensions in 
closed vessels.  
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APPENDIX 
Materials 
Instrumentation 
and 
Procedures 
1 Materials, Reagents and solvents.  
Materials, Reagents and solvents were obtained from Acros Organics (Geel, 
Belgium), ABCR (Karlsruhe, Germany), Alfa Aesar (Ward Hill, USA), BDH 
Prolabo (Leuven, Belgium), ChemLab (Zedelgem, Belgium), Fisher Scientific 
(Loughborough, UK), Iris Biotech GmbH (Marktredwitz, Germany), 
Polysciences, Inc. (Eppelheim, Germany), Sigma-Aldrich (Bornem, Belgium), 
VWR chemicals (Leuven, Belgium), and were used without further purification. 
2 FT-IR spectroscopy 
FT-IR spectra were measured by using a Bruker Vertex 70 FT-IR spectrometer 
(Bruker, Ettlingen, Germany) equipped with a Platinum ATR accessory. Data was 
processed with OPUS 6.5 software. 
3 Mass spectrometry 
Electrospray ionisation mass spectroscopy (ESI-MS) was conducted on a Thermo 
Electron LCQ Advantage mass spectrometer with an ion trap analyzer, an Agilent 
1100 HPLC injection system and the Xcalibur data processing software. LC-MS 
was performed on an Alltech Prevail RP-C18 5 µm 150 mm x 2,1 mm column 
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coupled to an Agilent 1100 degasser, quaternary pump, auto sampler, UV-DAD 
detector and thermostated column module coupled to Agilent 6110 single-
quadrupole MS. Use of Agilent LC/MSD Chemstation software. 
4 HPLC 
Preparative HPLC was performed on a Waters Delta 600 system equipped with a 
Waters 996 Photo Diode Array detector. An Alltech C18 Prevail (5 µm, 150 mm x 
22 mm) was employed. 
5 NMR spectroscopy 
1H and 13C NMR spectra were recorded by using a Bruker Avance 300 
spectrometer, operating at 300 MHz for 1H and 75 MHz for 13C, a Bruker Avance 
400 spectrometer, operating at 400 MHz for 1H and 100 MHz for 13C, or a Bruker 
Avance III 600 spectrometer, operating at 600 MHz for 1H and 150 MHz for 13C 
(Bruker, Karlsruhe, Germany). Chemical shifts are reported in parts per million 
(ppm) and are referenced to the internal standard tetramethylsilane. For 13C 
spectra, residual solvent signals are used as the internal standard. Spectra are taken 
at room temperature unless otherwise stated. 
6 Proton NMRD 
Proton nuclear magnetic relaxation dispersion (NMRD) profiles were measured on 
a Stelar Spinmaster FFC, fast field cycling NMR relaxometer (Stelar, Mede (PV), 
Italy) over a magnetic field strength range extending from 0.24 mT to 0.7 T. 
Measurements were performed at 310 K on 0.6 mL samples contained in 10 mm 
o.d. pyrex tubes. Additional relaxation rates at 20, 60, 300 and 500 MHz were 
respectively obtained on a Minispec mq-20, a Minispec mq-60, a Bruker Avance-
300 and a Bruker Avance 500 (Bruker, Karlsruhe, Germany). 
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7 TXRF spectrometry 
TXRF measurements were performed on a Bruker S2 Picofox  (Bruker, Berlin, 
Germany) with a molybdenum source and a Bruker AXS sample carrier. 100 µm 
sample solutions were added to 100 µl of a Chem-Lab gallium(III) standard 
solution (500 µg/mL, 2-5% HNO3). The resulting solution was drop casted on a 
hydrophobic quartz plate and dried in an oven at 60 °C to remove the solvent. 
Three quartz plates were made in the same manner and used to determine the 
concentrations. 
8 Magnetic Resonance Imaging 
Phantoms of NPs suspended in Eppendorf tubes containing 1.5% agar gel 
(microbiology grade, Sigma Aldrich, Bornem, Belgium) were prepared as 
previously reported.1,2 Hereby, total iron concentrations in the phantoms varied 
between 0 to 300 µg·ml-1. Similarly, phantoms were prepared containing SKOV3 
cells that were previously incubated overnight with NPs (50 g iron/ ml medium).2 
MRI experiments of phantoms were performed as previously described.1,2 Briefly, 
a Bruker Biospec 9.4 T small animal MR scanner (Bruker Biospin, Ettlingen, 
Germany, horizontal bore, 20 cm) equipped with actively shielded gradients (600 
mT·m-1) was used for all experiments. A quadrature radio-frequency 
transmit/receive resonator (inner diameter 7 cm, Bruker Biospin) was used for 
data acquisition. Measurements of the T2 relaxation times were performed using a 
multi-echo, spinecho pulse sequence with 24 echo time (TE) increments (first TE 
= 11 ms, increments of 11 ms; repetition time (TR) = 1500 ms, slice thickness 1 
mm, in-plane resolution 117 µm). Measurements of the T1 relaxation times were 
performed using a variable TR spin echo sequence with TE = 10 ms, 10 
increments of TR ranging from 155 to 5000 ms, slice thickness 1 mm, in-plane 
resolution 117 µm). Three-dimensional, high-resolution T2*-weighted MR images 
were acquired from phantoms containing cell suspensions and using a gradient 
echo sequence (FLASH, TR = 200 ms, TE = 15 ms, 15 excitation pulse of 15°). 
The field of view was 6.0 × 6.0 × 2 cm, resulting in an isotropic resolution of 117 
| APPENDIX 
 
149 
μm3. All images were processed with Paravision 5.1 (Bruker Biospin, Ettlingen, 
Germany). 
9 Optical spectroscopy 
UV-Vis absorption spectra were measured on a Varian Cary 5000 
spectrophotometer on freshly prepared aqua solutions in quartz Suprasil® cells 
(115F-QS) with an optical path-length of 1.0 cm. 
Emission data were recorded on an Edinburgh Instruments FLS980 steady-state 
spectrofluorimeter. With a continuous xenon lamp (Xe1) and a standard PMT 
(Hamamatsu type R928P). It is equipped with a double grating monochromator 
and an automatic filter wheel to remove 2nd order effects. Luminescence decays, 
excitation, and emission data were recorded on an Edinburgh Instruments FS900 
or FS920 steady state spectrofluorimeter. These instruments are equipped with a 
450 W xenon arc lamp, a high energy microsecond flash lamp μF900H and an 
extended red-sensitive photomultiplier (185–1010 nm, Hamamatsu R 2658P). All 
spectra are corrected for the instrumental functions. Luminescence decays were 
determined under ligand excitation monitoring emission of the most intense 
transitions of the luminescent lanthanide. Luminescence decays were analyzed 
using Edinburgh software and lifetimes were averages of at least three 
measurements in water and deuterated water. Quantum yields were determined by 
a comparative method with an estimated experimental error of ± 10% using a 
solution Rhodamine 101 (Sigma) in ethanol (Q = 100%) and Rhodamine 6G (Q = 
76%) in water as standards. The solutions are diluted to get an optical density 
lower than 0.05 at the excitation wavelength. 
The two-photon fluorescence microscopy samples were prepared by drop casting 
the functionalized nanoparticles in water on microscopy slides, after which the 
samples were allowed to dry for several hours. Two-photon microscopy 
experiments were conducted on a commercial Olympus BX61WI-FV1200-M 
system (Olympus, Münster, Germany). The fundamental wavelength was set to 
1100 nm (120 fs pulse width, 80 MHz pulse repetition rate) on the InSight DS+ 
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laser of Spectra Physics. The polarization of the fundamental beam was controlled 
using a Glan-laser polarizer. For detection at 550 nm, a 560 lpxr dichroic mirror of 
Chroma was installed in front of the detector. Detection was carried out non-
descanned in backward reflection using a photon counter detector of Hamamatsu 
R3896 (Hamamatsu Photonics Co., Hamamatsu, Japan). The images (640 × 640 
pixels) were recorded with a 15× Thorlabs LMV objective (NA of 0.3) and a pixel 
dwell time of 200 ms. 
10 High content image analysis of cell viability 
The NPs were tested for cellular interaction and their effect on cellular viability in 
five primary and immortalized, carcinoma and normal mammalian and rat cell 
types. These were: the human umbilical vein endothelial (HUVEC), human 
hepatic stellate (GRX), human ovarian carcinoma (SKOV3), rat exocrine 
pancreatic tumor (AR42J) and rat insulinoma (INS1) cells. Cells were seeded in 
96 well plates at a concentration of 3500 cells per well in 250 µl full cell medium 
and allowed to settle overnight in a humidified (5% CO2) incubator set at 37 °C. 
Next day, each cell type was exposed to the NPs at 0, 5, 10, 25, 50, 100, and 200 
µg/ml concentrations in triplicate for 24 h. Following the exposure period the cells 
were washed twice with phosphate buffered saline (PBS; Gibco, Invitrogen, 
Belgium) and treated with 2 µM fixable Live-Dead green (Molecular Probes, Life 
Technologies Europe, BV, Belgium) dead cell stain in 250 µl full cell 
medium/well for 30 min at 37 °C. The stain was removed by washing once with 
PBS and fresh medium was added to each well (250 µl/well) and incubated for 
further 30 min at 37 °C in a 5% CO2. Finally, cells were fixed with 4% 
paraformaldehyde for 10 min at room temperature. The fixative was removed and 
cells were washed once with PBS. The nuclei were counterstained with Hoechst 
33342 solution (Life Technologies Europe, BV, Belgium) after which cells were 
washed twice with PBS and each well was aliquoted with 500 µl of PBS. Plates 
were analyzed on the InCell analyser2000 (GE Healthcare Life Sciences, 
Belgium) where fluorescence-based images for the blue (nucleus), green (dead 
cells) and red (NPs) channels were collected at a minimum of 2000 cells per 
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replicate. Acquired data was analyzed using the InCell Developer software (GE 
Healthcare Life Sciences, Belgium).  
11 Flow setup 
The flow setup was constructed with copper GC tubing (0,065” inner diameter, 
Restek) and the reagents are pumped using a Chemyx Fusion 200 syringe pump.  
12 Determination of q 
Luminescence decays of the metallostar complexes have been measured in water 
and D2O under ligand excitation (270-315 nm). The transitions 5D0→7F2, 5D4→7F5 
and 4F9/2→6H13/2 of Eu(III), Tb(III) and Dy(III) respectively, were monitored and 
analyzed using the Edinburugh software and lifetimes were averages of at least 
three measurements. The decrease of the luminescence lifetime in water compared 
to D2O is due to the presence of inner sphere high-energy O-H vibrations and can 
be used for determining the number of coordinated water molecules. The best fit 
was observed by applying a bi-exponential decay, which suggests the presence of 
two different species in solution. The following phenomenological equation3–6 for 
Ln(III)-polyaminocarboxylate systems have been employed to determine the 
hydration number q with an accuracy of ± 0.1-0.3: 
𝑞Eu (H2O) = 1.11(Δkobs − 0.31 + 0.44qOH + 0.99qNH + 0.075qCONH) (eq. 1) 
𝑞Dy (H2O) = 21.1 ∙ Δkobs − 0.60 (eq. 2) 
𝑞Tb (H2O) = 5(Δkobs − 0.06) (eq. 3) 
 
Δkobs represents the difference of the decay rate constants 𝑘𝐻2𝑂(1 𝜏𝐻2𝑂)⁄  and 
𝑘𝐷2𝑂(1 𝜏𝐷2𝑂)⁄ , expressed in ms-1 for Eu(III) and Tb(III) and µs-1 for Dy(III). The 
qX, stands for the number of OH, NH or CONH groups directly bound to the 
lanthanide center. 
APPENDIX | 
 
152 
13 Quantum yield 
The luminescent quantum yields 𝑄𝐿𝐿𝑛 were determined upon ligand excitation by a 
comparative method, using a solution of Rhodamine 101 in ethanol (Q = 100%) or 
Rhodamine 6G in water (Q = 78%)7 as the standard. Solutions were prepared in 
order to obtain an optical density in the range of 0.02-0.05 at the excitation 
wavelength. The quantum yield was determined according to the following 
equation: 
𝑄𝐿 = 𝑄𝑆 ∙ 𝐼𝑋𝐼𝑆 ∙ 𝐴𝑆(𝜆𝑒𝑥𝑐)𝐴𝑋(𝜆𝑒𝑥𝑐) ∙ 𝜂𝑋2𝜂𝑆2  (eq. 4) 
 
In this equation, the s and x refer to the standard and the unknown sample 
respectively, I represents the corrected total integrated emission intensity, A is the 
absorbance at the excitation wavelength and η the refractive index of the solution 
(ηwater = 1.34 and ηethanol = 1.36). Direct excitation into the lanthanides is possible 
but is very inefficient because the f-f transitions are Laporte forbidden. The 
intrinsic quantum yields 𝑄𝐿𝑛𝐿𝑛 (Ln = Eu(III), Tb(III)) can however be estimated 
according to the following equations comprising the ratio between the observed 
(τobs) and radiative (τrad) lifetimes. 
1 τ𝑟𝑎𝑑 =  𝐴𝑀𝐷,0 ∙ 𝑛3 ∙ �𝐼𝑡𝑜𝑡𝐼𝑀𝐷� (eq. 5) 
𝑄𝐿𝑛
𝐿𝑛 =  τ𝑜𝑏𝑠
τ𝑟𝑎𝑑
 (eq. 6) 
 
The Einstein coefficient AMD,0 equals 14.65 s-1, n is the refractive index set to n𝐻2𝑂 = 1.34, which is equal to that of the neat solvent, and (Itot/IMD) represents the 
ratio of the total integrated intensity of the transitions to the transition of the 
magnetic dipole (MD). Sensitization efficiency of europium complexes (ηsens) 
gives an idea about the efficiency of energy transfer from the ligand to the 
lanthanide ion and is defined by the ratio between the quantum yield under ligand 
excitation and the intrinsic quantum yield:  
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𝜂𝑠𝑒𝑛𝑠 =  𝑄𝐿𝐸𝑢𝑄𝐸𝑢𝐸𝑢 (eq. 7) 
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